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Abstract
Introduction Infection is the main source of morbidity and mortality in cystic fi-
brosis (CF). In recent years, understanding of infection in CF patients has increased
dramatically due to the advent of next-generation sequencing technology. This has al-
lowed a culture-independent approach to studying entire communities of bacteria, the
microbiome, living within the CF lung, and thus avoiding bias of culture-based tech-
niques. Microbiome studies have revealed associations between microbial community
structures in the CF lung and clinical outcome measures of the patients, such as pul-
monary function and exacerbation status. In addition, microbiome studies in CF have
enabled identification of potential pathogens which are difficult to cultivate. Though
the lung microbiota in CF is gaining recognition, the role of other bacterial commu-
nities in CF remains unchartered. This study aims to assess feasibility of isolating
bacterial DNA from the skin, nare, and oropharynx of children with CF and provide
pilot data for a study into the culture-based and culture-independent microbiomes of
children with CF compared to healthy controls.
Methodology 18 CF patients, 17 healthy controls, and 1 subject with equivocal
diagnosis were recruited into a study exploring the bacterial communities in the ante-
cubital fossa, forearm, axilla, nare, and oropharynx. Culture swabs and swabs for DNA
extraction were collected from patients. In addition, clinical information was collected
from each subject.
i
Results DNA was isolated from swabs and libraries prepared for sequencing of
hypervariable region 4 in the 16S gene showing significant overlap in all sites between
both CF patients and healthy controls. Culture-swabs of both CF subjects and healthy
controls demonstrated frequent isolation of Pseudomonas in all sites examined. Pseu-
domonas was isolated from the skin in 11.1% and nare or oropharynx in 22.2% of CF
subjects (n=18), and was also isolated on the skin in 23.5% and nare or oropharynx
in 11.8% of healthy subjects (n=17). In addition, Staphylococcus aureus was isolated
from the skin of some CF patients but no healthy controls.
Discussion This study is the first step in a feasibility study to determine the role
of the microbiome in CF infection and can charter transmission events. Unexpectedly,
a high proportion of healthy controls were colonised with Pseudomonas and only CF
patients were colonised with S. aureus which merits further exploration.
ii
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Chapter 1
Introduction
1.1 Cystic fibrosis
Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene which encodes
a chloride channel. Recurrent chest infections are the primary cause of morbity and
mortality in CF though it is a systemic disease with other pertinent manifestations in
the gastrointestinal tract. CF has an incidence of 1 in 2000-3000 births in caucasian
populations, as such approximately 1 in 26 caucasians carry a CF-causing mutation[1].
It is the most common life-threatening genetic disorder in the Western world and carries
a median predicted survival of 41.1 years as of 2012[2].
1.2 Epidemiology
CF is strongly associated with European descent, however its incidence varies substan-
tially across different regions, with some having population-specific mutations[1].
This high incidence of a severe genetic disease has lead to speculation surrounding
a selective advantage for carrier status in preventing dehydration during diarrhoeal
diseases such cholera[3] and typhoid[4], though this has been challenged[5]. It is esti-
mated F508del originated 11,000 to 34,000 years ago, likely in a pre-Neolithic era and
predating modern humans, although a place of origin has not been determined[6, 7].
1.3 CFTR
The CFTR gene is found on the long arm of chromosome 7, encoding a 1.7kDa chlo-
ride ion within the ATP-binding-cassette transporter superfamily and comprises two
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membrane-spanning domains, two nucleotide-binding domains, and a regulatory do-
main[8], see figure 1.1. Over 1800 CFTR variants have been characteristed to date
(http://www.cftr2.org/), most of which are known to cause CF. The most common
CF-causing mutation is deletion of phenylalanine at postion 508 (F508del), causing
two thirds of cases worldwide[1].
CF-causing mutations can be divided into six classes, depending on the mechanism
in which they cause disease. Class I mutations prevent initial synthesis of CFTR;
Class II mutations, such as F508del, result in defective processing of CFTR within
the cell; Class III mutations cause defects in the regulation of CFTR though it is
able to reach the apical membrane; Class IV mutations lead to decreased conductance
of CFTR; and Class V mutations result in decreased synthesis of CFTR[9]. A sixth
class was added later, encompassing CF mutations where there is increased turnover
of CFTR[10]. Mutation classes I-III are regarded as causing severe disease since there
is nearly no functional CFTR present[11], however genotype only partially determines
disease severity with other factors being implicated such as genes regulating immune
response and susceptibility to infection, as well as environmental factors[12].
1.4 Pathogenesis
1.4.1 CFTR ion channel
The apical surface of epithelial cells in the airway are coated in airway surface liquid
(ASL), which can be divided into the upper mucus layer and the periciliary liquid layer
(PCL)[14]. The PCL forms an interface between the upper mucus layer and epithelial
cells, enabling the mucocilliary escalator to function in a low viscosity liquid while
allowing the mucus layer to act as a physical barrier against inhaled pathogens[15].
In cystic fibrosis, the lack of CFTR not only prevents chloride ions being transported
through the apical membrane into the PCL, but also leads to upregulation of the
epithelial sodium channel (ENaC) through mechanisms that remain obscure[16]. This
results in increased sodium ion uptake into epithelial cells through ENaC and chloride
paracellular transport, and thus water follows from the ASL into the epithelial cells.
Dehydration of the ASL leads to a decreased volume of ASL with more viscous and
2
R-domain
MSD-2 MSD-1
NBD-2 NBD-1
Figure 1.1: CFTR protein
R-domain indicates regulatory domain, MSD indicates membrane spanning domain,
NBD indicates nucleotide-binding domain. Loops indicate α-helices while ribbons
indicate βsheets. Modelled on Sav1826[13], rendered with Pymol.
adherent mucus in the airways, which coupled with a lack of mucocilliary function leads
to bacterial colonisation[17].
A similar pattern of disease is seen in other mucous lined luminal organs within
CF patients, as such common complications include exocrine pancreatic insufficiency,
vitamin deficiencies, diabetes mellitus, liver disease, meconium ileus and its adult equiv-
alent, distal intestinal obstructive syndrome[18].
1.4.2 Secondary functions of CFTR
CFTR has been demonstrated to act as a receptor to internalise smooth Pseudomonas
aeruginosa, a dominant CF pathogen, with intact pili, into epithelial cells[19] but not
other common respiratory pathogens[20]. The impact of P. aeruginosa internalisation
is debated, with some studies finding increased bacterial clearance[19], while others
show mutant CFTR leads to increased uptake of P. aeruginosa with increased survival
and replication of some strains[21].
Furthermore, CFTR has been found on non-polarized cells. In macrophages from CFTR
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knock-out mice, there is reduced killing of P. aeruginosa compared to wild-type due
to a less acidic environment within the phagosome; likely because mutant CFTR is
unable to transport Cl- which provides a counterion effect to increase H+ within the
phagosome[22]. Similar defects have been found in phagosomes from neutrophil-like
cells[23]. Dysfunctional innate immune responses are consistent with inability to clear
inhaled pathogens in CF despite high numbers of neutrophils in the airways[24].
1.4.3 Immune responses
Dysfunctional immune response plays a key role in damage of CF airways. Defects may
be caused by CFTR directly, as discussed previously, or acquired through exposure of
the CF lung to pathogens. Neutrophilic infiltration is a hallmark of the CF lung[24],
likely due to activation of respiratory epithelial cell Toll-like receptors by respiratory
pathogens, leading to potent neutrophil influx via interleukin-8 (IL-8)[25]. In addition,
the P. aeruginosa flagellum can bind to the glycolipid asioloGM1 on the surface of
epithelial cells, eliciting a strong nuclear factor-κB mediated inflammatory response.
This enables greater IL-8 production, thus leading to greater neutrophil recruitment[25].
In the presence of persistently high levels of proinflammatory cytokines such as IL-
8, or bacterial molecules such as lipopolysaccharide, neutrophils have a propensity to
degranulate causing damage to the host.[25] Moreover, with high levels of neutrophil
infiltration and degranulation, neutrophil serine proteases are released, which are detri-
mental to the phagocytic and bacterial killing functions of nearby neutrophils through
cleavage of the complement 5a receptor [26] and CXCR1 (IL-8 receptor, alpha)[27] on
the cell surface. The extent to which immune changes in CF are directly mediated by
CFTR as opposed to acquired changes in the airway environment is not yet clear.
1.5 Natural history
1.5.1 Screening and diagnosis
Previously, children with CF would present either with meconium ileus at birth (13-
17% of patients) or in early childhood usually with gastrointestinal symptoms, initially
lacking respiratory symptoms[28, 29]. Presentation later in life is associated with pan-
creatic sufficiency, and diagnosis is typically prompted by recurrent chest infections
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or infertility[29]. Infants with CF are increasingly identified by newborn screening
(NBS), exploiting high levels of immunoreactive trypsinogen (IRT) found in the serum
of CF infants in the first days of life. However, this test lacks sensitivity, meaning
most NBS protocols adopt a multi-tier approach incorporating DNA testing prior to
diagnostic pilocarpine iontophoresis (commonly known as the sweat test)[30]. Two or
more sweat tests of greater than 60mmol/L of chloride in sweat is the gold standard
for diagnosis[29]. Due to the lack of sensitivity, NBS can identify carriers and infants
with equivocal diagnosis whose natural history remains unclear[31]. These are previ-
ously unrecognised groups of infants with at least one CF mutation of unclear clinical
consequence or one CF-causing mutation and an intermediate sweat chloride level (30-
59mmol/L chloride on pilocarpine electrophoresis)[31]. These new challenges underpin
the heterogenous nature of CF.
There is evidence from infants identified by NBS that structural lung damage may be
present from as early as 3 months of age in addition to colonisation with CF pathogens,
such as P. aeruginosa[32], although these may be independent events. This highlights
the importance of early respiratory interventions to curtail development of lung damage
and consideration of infection with significant CF pathogens early. Over recent years,
life expectancy and quality of life in CF have improved dramatically which is thought
to be largely related to more proactive measures to prevent and treat infection, in
addition to closer monitoring of nutritional status[33]. Despite this, most patients with
CF develop chronic chest infections and die of respiratory failure before their fifth
decade[2].
1.5.2 CF pulmonary exacerbation
CF pulmonary exacerbation (CFPE) is characterised by sudden increase in symptoms
experienced by patients and is associated with detrimental long-term outcomes, particu-
larly progressive lung disease and bronchiectasis in both children[34, 35] and adults[35].
Although CFPE is associated with significant clinical outcomes, little is known about
the underlying mechanism although there is association with both host immune changes
and changes in lung microbiology[36]. Price et al [37] find adults with CF have no change
in the diversity or bacterial genera present during CFPE, and no change in bacterial
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load. This is consistent with a study in adults suggesting there is no acquisition of
new P. aeruginosa strains during CFPE[38]. Viral infection has been associated with
CFPE in addition to colonisation with pathogens[39], although viral infection in CF
has not been well studied and the impact of these will likely be revealed in well-designed
metagenomic studies. Moreover, high levels of pro-inflammatory cytokines have been
found in airways during CFPE[36], and although the reasons behind this have yet to
be elucidated, this provides an explanation for long-term damage of airways due to
CFPE.
1.6 Typical CF pathogens
Evaluation of CF patients for pathogens is driven by culture-based techniques. There
are limitations on groups of organisms which can be cultured using standard micro-
biological techniques. In addition, children with CF are often unable to expectoriate
sputum, particularly prior to chronic P. aeruginosa infection. As such, oropharyngeal
swabs are used instead, however throat swabs do not accurately reflect the lower air-
ways. Armstrong et al found oropharnyngeal swabs to have a poor negative predictive
value for CF pathogens when compared with bronchoalveolar lavage in the same pa-
tient group[40]. Furthermore, some of the major CF pathogens, notably Staphylococcus
aureus and non-typable Haemophilus influnenzae, can colonize the upper respiratory
tract in health, thus their roles as pathogens when found in the lower respiratory tract
is not clear.
There is a trend for CF lung infections to start with S. aureus and H. influenzae
either on their own or together as a coinfection in early childhood, and with progressive
lung damage P. aeruginosa and other significant pathogens become dominant[41, 42].
1.6.1 Staphylococcus aureus
S. aureus is a Gram-positive coccus, typically associated with large golden-yellow
colonies, β-haemolysis on blood agar, and grape-like clusters on microscopy[43]. Though
it is widely regarded as aerobic, it may also grow as a facultative anaerobe and can
produce biofilms[44]. It is a skin commensal, usually residing in the anterior nares[45],
but also found in moist areas of the skin such as those dominated by apocrine glands in
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the axilla and groin[46]. It is also a pathogen responsible for skin infections and early
chest infections in CF patients[43]. Williams[46] and Kluytmans[47] postulate there are
three distinct groups of the population - those who persistently carry S. aureus (10-
20%), those who intermittently carry (20-75%) and those who rarely carry (5-50%).
Gamblin et al present a more recent study from a UK population, estimating a 27%
nasal carriage rate[48]. Prevalence of S. aureus in the nares of children with cystic
fibrosis taking anti-staphylococcal prophylactic antibiotics is 29%, while those without
prophylaxis carry at 57%, much higher than the general population[49].
Airway inflammation and damage associated with S. aureus infection is postulated
to create a niche for P. aeruginosa infection later in life[41, 42]. As such, in the UK anti-
Staphylococcal antibiotics are given from diagnosis in attempt to prevent this infection,
and although some have argued this leads to an increase in P. aeruginosa infection,
overall there is clinical benefit[50]. Methicillin-resistant Staphylococcus aureus (MRSA)
infection, previously thought to only occur as a nosocomial infection, is an emerging
problem in CF chest infections[42].
1.6.2 Haemophilus influenzae
H. influenzae is a non-motile Gram-negative coccobacillus which is a facultative anaer-
obe and can form biofilms[51, 52]. It is generally divided into encapsulated strains for
which there are six serotypes, and unencapsulated strains[53]. H. influenzae was also
the first complete bacterial genome to be sequenced[54]. It is a normal commensal of the
upper respiratory tract and is known only to cause disease in humans; primarily otitis
media and upper respiratory tract infections in children, in addition to lower respiratory
tract infections in CF[55]. Serotype b is particularly virulent, causing meningitis, how-
ever this has been largely eradicated in the Western world since routine immunisation
against this serotype with the Hib vaccine.
1.6.3 Pseudomonas aeruginosa
P. aeruginosa is a Gram-negative aerobic bacillus which is usually motile with a single
flagellum, although non-motile isolates are often found in clinical isolates from CF
sputum[56]. Though traditionally considered aerobic, it is a faculative anaerobe and
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has the ability to form biofilms[57]. Its morphology can be broadly categorised into
non-mucoid and mucoid due to excessive alginate production, the latter being typical of
clinical isolates from CF patients with chronic P. aeruginosa infection[56]. Moreover,
P. aeruginosa can secrete a variety of pigments which may stain solid media, ranging
from blue (pyocyanin) through to black (pyomelanin). These pigments are thought
to have important roles in virulence, cell adhesion, and siderophore activity[58–60].
It is an opportunistic pathogen in animals and plants[61]. In humans, it is primarily
associated with infection in burn wounds and immunocompromised patients in a variety
of sites, ranging from chest, urinary tract, and gastrointestinal infections, through to
sepsis, and is widely regarded to be the most dominant pathogen in the CF lung[56].
1.6.4 Burkholderia cepacia complex
Burkholderia cepacia complex are a group of bacteria belonging to the Burkholderia
genus, which through next-generation sequencing, is estimated to comprise at least 17
species, however routine biochemical testing cannot currently distinguish these ade-
quately[62, 63]. It is ubiquitous in the environment and was initially identified as a
plant pathogen but many species have subsequently been demonstrated to be benefi-
cial to plants[63]. In CF patients, it may be carried asymptomatically, lead to chronic
infection, or lead to the fatal ”cepacia syndrome” where a sudden decrease in clinical
status followed by sepsis is seen, unlike other CF pathogens[63].
1.6.5 non-Tuberculosis mycobacteria
non-Tuberculosis mycobacteria (NTM) have been implicated in CF infections increas-
ingly over recent decades[64], especially Mycobacerium abscessus. It has emerged that
there are likely to be three subspecies of M. abscessus identified through whole-genome
sequencing; subsp abscessus, subsp massiliense and subsp bolletii, although currently
they cannot be distinguished by standard techniques[65]. NTM were thought to be
acquired from the environment, however recently it was discovered subsp massiliense
likely undergoes person-to-person transmission[66]. Patients infected with NTM have
an unclear clinical outlook, with some patients carrying at low levels asymptomati-
cally, while others experience a drastic decline in lung function associated with this
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group of pathogens[64]. It is currently debated whether treatment of this pathogen is
necessary[64].
1.6.6 Achromobacter xylosoxidans
Achromobacter xylosoxidans is a ubiquitous environmental species regarded as an op-
portunistic pathogen, especially in CF where it has been reportedly been increasing in
prevalence of CF patients infected[67]. The clinical importance of colonisation with A.
xylosoxidans, like NTM, is debated[67]. Isolates of A. xylosoxidans from CF patients
typically have high levels of antibiotic resistance, with some genomic determinants of
resistance (specific resistance integrons) being linked to greater biofilm formation[68].
Though there have been evidence of outbreaks of A. xylosoxidans in hospitals through
disinfectant solutions, saline, and dialysis fluid, there is little evidence of person-to-
person transmission[69].
1.7 Microbiomes
The human body is populated by a rich plethora of microorganisms including archaea,
bacteria, viruses and fungi. It is estimated bacterial cells outnumber human cells by a
factor of ten[70]. These microorganisms reside on the topological surface of the human
which can be divided into distinct niches within the gut, respiratory tract, urogenital
tract, and integumentary system[71]. The community of microorganisms is defined as
the “microbiota” and this alongside the environment they reside is termed the “micro-
biome”[72]. The human microbiota encompasses a community with complex interac-
tions between each other and their host, contributing to host immunity, metabolism,
and disease[73]. Molecular techniques to study microbial communities have become
the standard approach, with increasing recognition that a significant proportion of
the bacterial kingdom cannot be cultured under standard laboratory conditions[74].
As next-generation sequencing technology has decreased in cost, it has provided the
primary means of investigating the microbiome[75].
Interest in the human microbiome culminated in the Human Microbiome Project
(HMP), exploring the microbiota of 300 heathy adults[71]. The project involved sam-
pling 15 and 18 specific niches, from males and females respectively, in each subject
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and in some subjects multiple samples were taken to study temporal variation in the
microbiome[76]. Next-generation sequencing technology was exploited to determine
community members and structure, in addition to functional metabolic components of
each microbiome[77]. This important project resulted in an understanding of the vari-
abtion between normal microbiomes in adults and a strong contribution of reference
genomes, providing a foundation for study of the microbiome in disease settings.
1.8 Community ecology methods
Microbiome analysis involves not only surveying abundance of members of the commu-
nity present, but also the structure of the community; how diverse the community is
and the degree of evenness in distribution of abundance[78]. An ecological approach is
important to understanding microbiota in disease states, for example antibiotic therapy
leads to community disturbances and after discontinuation of therapy, the community
reassembles[79]. Ecological approaches to the microbiome have stemmed largely from
plants and animals with subtle differences in the way in which this ecosystem is ob-
served; usually employing DNA sequencing or community fingerprinting techniques[80].
These techniques will delineate taxonomic units within a sample, termed operational
taxonomic units, which represent individuals at a species or genus level, depending on
level of genetic distance from the rest of the community.
1.8.1 Alpha diversity
Alpha diversity is a commonly used metric in microbiome studies to describe the culmi-
nation of richness (the number of different species present) and evenness (distribution of
abundance of species) within a sample[80]. Commonly used metrics for alpha diversity
include the Shannon index[81]:
H ′ = −
S∑
i=1
(pi ln(pi))
and Simpson index[81]:
D =
S∑
i=1
p2i
where pi is the fraction of the community made up by abundance of species i and S is
the total number of species in the community.
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These metrics are calculated with OTU approximations of species-level taxa present.[80]
Alpha diversity is thought to reflect ecological flux and stability in a community; it
has been speculated that high alpha diversity protects from invasion of pathogenic bac-
teria[82]. This is of great clinical consequence as antibiotic therapy has been shown to
reduce alpha diversity, and it is postulated this may create a niche for CF pathogens[80].
Many of the factors contributing to alpha diversity in microbiome studies, however, have
not yet been elucidated[80], and many published microbiome studies do not demon-
strate causation between environmental parameters and alpha diversity.
1.8.2 Beta diversity
Beta diversity compares overlap in taxa present in different microbiomes, and is usually
given as a measure of dissimilarity between them, the Bray-Curtis index[81]:
BCij =
Si + Sj − 2Cij
Si + Sj
where Si is the number of OTUs found in site i, Sj is the number of OTUs found in
site j, and Sij is the sum of abundance of shared OTUs, using the value from the site
of least abundance.
Beta diversity relates to one of the initial questions of the HMP, as to whether adults
had a core microbiome between sites and between each other[70]. It is now postulated
a core microbiome is likely not to exist as high beta diversity is observed both within
the individual microbiomes and even higher beta diversity between microbiomes from
different individuals[80].
1.9 16S ribosomal RNA gene
16S ribosomal RNA (rRNA) is an integral part of the bacterial 30S subunit and its
nucleic acid sequence carries phylogenetic signal[83]. As such, the gene encoding 16S
rRNA is a widely-used target to study microbial communities, in identifying community
members and determining the phylogenetic distributions of prokaryotes. The 18S rRNA
gene is the eukaryotic equivalent[84].
The 16S rRNA gene is approximately 1.5kb and comprises nine hypervariable re-
gions (V1-V9) interspaced with conserved regions[85]. Each bacterial genome carries
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multiple copies of 16S, which may need to be accounted for in downstream analyses[86].
Each hypervariable region carries a distinct specificity for detection of particular taxo-
nomic lineages[87] so the choice of hypervariable region is dependent on the expected
taxonomic composition of the microbial community. In addition, intragenomic het-
erogeneity within 16S genes in each taxon must be considered[88] as this would ar-
tificially increase the diversity of taxa observed. This is particularly important for
extremophiles where large insertions in 16S may be adaptive to render some copies
of 16S non-functional[88]. V4 and V5 regions display the least intragenomic hetero-
geneity[88], supporting use of these regions in studies comparing microbial community
structures.
A variety of methods have employed the 16S gene to study microbial communities,
from electrophoresis-based methods to next-generation sequencing.
1.10 Community fingerprinting techniques
Community fingerprinting techniques provide a snapshot at one particular time of a
microbial community structure. They all start with extracting total DNA from directly
from the sample without culture, and then proceed to amplify a particular gene product
using the polymerase chain reaction (PCR), usually within the 16S region for microbial
ecology[89]. The most commonly used techniques have been described, though they
have largely been superseded by next-generation sequencing approaches.
1.10.1 Temperature and Denaturing gradient gel electrophoresis
Temperature gradient gel electrophoresis (TGGE) is performed by running PCR prod-
ucts of the 16S region on a polyacrylamide gel moving up a gradient of temperatures,
and relying on differences between taxa in GC content of 16S; as the DNA melts, it
forms a band through use of a GC clamp[90]. This method has been refined using a
denaturant, formamide, to melt DNA rather than a temperature gradient. It has been
criticised for lack of reproducibility, its qualitative nature, and inability to determine
phylogeny[91].
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1.10.2 Terminal restriction fragment length polymorphism
Terminal restriction fragment length polymorphism (T-RFLP)is a technique based on
PCR with a 5’ fluorescently labelled primer for a specific region, in this case usually the
16S gene or another gene with strong phylogenetic signal, followed by treatment with
restriction endonuclease enzymes[92]. After size selection for the terminal fragments
(the 5’ end of sequence containing the fluorescent probe, each assumed to represent an
OTU), the fluorescent intensity can be measured and plotted against fragment length,
producing an electropherogram[92].
1.10.3 Automated ribosomal intergenic spacer analysis
Ribosomal intergenic spacer analysis (RISA) takes advantage of the heterogeneity ob-
served in both length and sequence, even at strain level, in the intergenic region between
16S and 23S regions on the rRNA operon[93]. RISA initially consisted of performing
PCR on the intergenic region followed by polyacrylamide gel electrophoresis, however
due to the time-consuming nature of this protocol, an automated technique (ARISA)
was develope[93], whereby similar to T-RFLP, a fluorescent primer is used enable mea-
surement of fluorescence intensity and produce an electropherogram. Although some
bacteria may have multiple heterogeneous copies of the intergenic spacer region, falsly
increasing estimates of diversity, ARISA demonstrates greater resolution for rare taxa
compared to T-RFLP[94].
1.11 Next-generation sequencing
Next-generation sequencing has rapidly changed the way microbial communities are
explored. With decreased sequencing costs, microbiome studies are becoming increas-
ingly commonplace. Pyrosequencing was introduced by Roche with the 454 GS-FLX
(454 Life Sciences) as the first high-throughput sequencing technology[95], followed by
Illumina sequencing. Both technologies perform ”sequencing by synthesis,” whereby nu-
cleotides are incorporated into a DNA strand from the sample and sequence generated
based on either release of pyrophosphate in the case of pyrosequencing[95] or incor-
poration of a fluorescent base-pair in the case of Illumina[96]. Illumina platforms are
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currently the most commonly used technology for microbiome studies as the readlength
is adequate for hypervariable region sequencing (up to 2×300bp if using a dual index
approach, where the amplicon is sequenced from both 3’ and 5’ ends), the error rate is
low compared to other platforms, and many samples can be run in parallel by applying
unique barcodes to each sample[96].
Next-generation sequencing in microbiology has been applied to amplicon sequenc-
ing of 16S hypervariable regions, as mentioned previously. In addition, it has been
applied to performing metagenome analysis, whereby the entire DNA composition of
a microbial community is sequenced to provide a collection of full genomes[97]. How-
ever, this approach requires large quantities of DNA, is largely prohibitive in terms of
cost and provides unique computational issues in terms of assembling short reads from
the sequencing platform together to form individual microbial genomes[77]. It has the
advantage of a more in depth analysis of the genomic structures within the microbial
community and a full overview of viral, bacterial and fungal elements.
1.12 Development of the microbiome
Development of the human microbiome begins with colonisation of a previously unin-
habited niche. Traditionally it was thought amniotic fluid is sterile prior to rupture of
membranes. Bearfield et al[98] found in a sample of 48 women with intact membranes
admitted for elective caesarian section that 34 had evidence of bacteria in amniotic
fluid by universal bacterial PCR, 20 of which had Streptococcus species, and 7 had
Fusibacterium nucleatum, both common oral commensals. This study postulated that
oral commensals can translocate into the amniotic fluid in response to increased levels
of prostaglandins. The presence of bacteria in amniotic fluid is supported by Hitti et
al[99], where 5 of 14 patients admitted with premature labour and intact membranes
had positive universal bacterial PCR despite culture-negative amniotic fluid. Unfortu-
nately without culture-based methods it is difficult to comment on levels of bacterial
load present in healthy amniotic fluid and whether they are viable. During birth, ba-
bies are first exposed to maternal vaginal and faecal microbiota in the case of vaginal
delivery and to skin microbiota in the case of Caesarian section. Newborns delivered
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vaginally initially carry a microbiome dominated by their maternal vaginal and faecal
microbiota, which shows little variation between body site[100]. A similar pattern is
seen with maternal skin microbiota in those infants born by Caesarian section[100].
The initial microbiome may impact development of atopic conditions in infants, as an
association has been shown between Caesarian section and risk of eczema and asthma,
which may be mediated by Clostridium difficile colinisation[101].
The infant faecal[102] and skin microbiomes[103] increase in diversity within the
first months of life and show evidence of ecological succession, in the skin microbiome
there is differentiation towards specific microbiota for different skin sites, as is seen in
adults[71]. In the faecal microbiome of healthy and CF infants, significant alterations
correspond with environmental events, such as changes in feeding and health[102, 104].
Moreover in children with CF, respiratory microbiota increases in diversity over time
at a greater rate than the faecal microbiota and changes in community membership
coincide with one another[104]. A firm theory of how the healthy microbiome develops
is still lacking, as the patterns of microbiomes observed do not enable speculation
surrounding the roles of dispersal, immigration of new microorganisms, and selective
pressures in the differentiation of microbiomes.
1.13 Paranasal sinus microbiome
Nearly all CF patients have inflammatory paranasal sinus disease which tends to be
more widespread and severe than non-CF patients with sinusitis[105]. The paranasal
sinuses have mucus thickening as elsewhere in CF, however it differs to the CF lung
in its weaker immune response, decreased antibiotic bioavailability, and the different
nutritional resources available for bacteria[106]. The paranasal sinus may mimic the
hypoxic conditions found in the CF lung[107] and is postulated to afford pathogens
protection from the host immune system and antibiotic therapy[108]. P. aeruginosa
undergoes substantial diversification and evolution in the sinus, migrating to and from
the respiratory tract, conferring the sinus a pivotal role in the progression of chronic
lung infections in CF[106, 109].
The microbiota of paranasal sinuses in CF have received little attention, although
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typical CF pathogens including S. aureus, P. aeruginosa, and H. influenzae have been
cultured in the CF sinus with many other aerobic and anaerobic pathogens[110–116].
Furthermore, correlations have been observed between pathogens in sinuses and bron-
choalveolar lavage washings, particularly S. aureus[112, 115]. The concordance be-
tween pathogens isolated in sinus and airways increases with age, and on pulsed-field
gel electrophoresis (PFGE) the same strains are found in sinus and airways concomi-
tantly[114]. Culture-independent study of the paranasal sinus microbiota would ad-
vance understanding of this niche and the biological plausibility of interventions such
as sinus surgery which are currently being explored in CF patients[117–119].
1.14 Nasal microbiome
Nasal mucosal microbiota in CF has largely been explored in terms of a niche for S.
aureus. It is postulated S. aureus adheres to the nasal mucosa prior to respiratory tract
colonisation and infection[45]. In healthy children, S. aureus is cultured at a similar
frequency from nare and oropharynx, though S. aureus is found more frequently in
the oropharynx than nares in children with CF[120, 121]. This contradicts dogma of
the nare as the most important site for colonisation by S. aureus preceding infection.
Transmission of S. aureus between CF patients and household members has been re-
ported[121], though it is rare and host-host transmission is more likely in MRSA[122].
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1.15 Airway microbiome
1.15.1 Development of lung microbiota
The airway microbiome in CF is a field of growing interest though still in its infancy.
Initially the Human Microbiome Project excluded the lung as a priority organ since
the lungs were presumed to be sterile[123], though it is now suspected that healthy
lungs are colonised with commensal bacteria[124]. The temporal progression of infant
microbiota migrating to distinct compartments remains unclear although in CF, one
study suggests lung microbial communities are acquired from the GI tract[104]. This
is consistent with current theories that the mouth acts as a reservoir for infection in
CF through microaspiration, evidenced by similar microbiota in mouth washings and
airways of individual patients with cystic fibrosis[125].
During early childhood, the CF airway microbiota diversifies before declining and
phylogenetically clustering in later life[126]. Decreased alpha diversity is associated
with age[126, 127], decreased FEV1[127], and the presence of both P. aeruginosa and
long-term antibiotic therapy[127, 128]. The cause of decreased diversity over time in
the CF airway remains to be elucidated though it may represent development of an
ecological niche with increased lung damage. The confounding factor of antibiotic
treatment cannot be eliminated until prospective studies examine acquisition of P.
aeruginosa[129].
1.15.2 Respiratory microbiome in CF
Studies on CF airway microbiota have focussed on the impact of typical CF pathogens,
relationships with clinical parameters, and comparison of stable patients to those with
an exacerbation. Distinct patterns of CF airway microbiota have been described in
relation to presence of Pseudomonas and Streptococcus, in addition to antibiotic ex-
posure. Microbiota can be divided into core and satellite taxa based on their relative
abundance and persistence in time and space[130]. There is discordance over whether
members of core taxa, particularly P. aeruginosa, disturb the wider microbial com-
munity structure varying from reports of decreased number of taxa associated with P.
aeruginosa[128] to no effect on background microbiota[125].
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The CF airway microbiota in individual patients appears to be stable over time,
only decreasing in diversity during antibiotic therapy and returning to baseline within
one month[127, 131]. Interestingly, there seems to be no increase in bacterial density
during CF exacerbation[132] but increased P. aeruginosa virulence factors have been
documented[133]. The underlying mechanism of CF exacerbation is yet to be elucidated
though the decrease in diversity appears to be pivotal.
Pseudomonas predominance in a patient sample has been suggested to correlate
with patient outcome but not related to CF genotype, while Streptococcus abundance,
regardless of Pseudomonas fraction may indicate clinical stability[129]. The species
found in clinically stable patients by Filkins et al were chiefly oral Streptococcus and
Streptococcus milleri group (SMG)[129], contradicting Sibley et al who suggest SMG
is associated with exacerbations in CF[134]. Considering Streptococcus is an abundant
taxa in the CF airway microbiome[129, 130, 135] and its pathogenicity is unclear,
further studies should elucidate the underlying mechanisms.
1.15.3 Pathogen discovery in microbiome studies
In the era of culture-independent methods, many bacterial genera, particularly anaer-
obes, are emerging as potential CF pathogens. Though anaerobes have received much
attention in adult airway microbiomes, they tend to be more abundant in younger pa-
tients[126]. Tunney et al. demonstrates the anaerobic genera Prevotella and Veillonella
can form the predominant bacterial fraction in CF patient sputum, predominating 18
of 40 and 13 of 40 patients studied respectively[136]. Supernatant from Prevotella in-
termedia grown in an anaerobic environment has been shown to be more virulent than
supernatant from P. aeruginosa grown in anaerobic conditions, both in vitro and in
vivo, however murine lung infection using an agar beads model did not result in mor-
tality[137]. This is likely due to limitations of the model and possibly inoculation of a
sub-infectious dose; 106 CFUs were used in the model compared to an upper limit of
107 found in patient sputum. Further studies investigating the role of anaerobic species
in the CF airway are necessary to understand these previously overlooked members of
the community.
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1.15.4 Lung allograft microbiome
The sinus may not act only as a hiding place for pathogens during antibiotic treatment,
but also as a reservoir for infection of the allograft following lung transplant[138, 139].
Remarkably, there appears to be little association between colonisation with typical
CF pathogen and outcome after lung transplant, apart from B. cepacia genomovar
III which carries a high mortality rate following transplantation[139]. Studies on CF
lung transplant microbiomes are limited, however one conference abstract reports Pro-
teobacteria being the dominant phylum, with phylogenetic diversity increasing for the
first nine months before decreasing[140]. These findings in the microbial communi-
ties of CF lung allografts deserve further investigation, especially in the context of the
potential role for allograft microbiome in the development of bronchiolitis obliterans
syndrome[139, 141], one of the most lethal complications of lung transplant.
1.16 Gastrointestinal microbiome
The gastrointestinal tract can be split into several components, each with a distinct
microbiome. The oral cavity, distal colon and faeces have received the most atten-
tion due to ease of sampling[142]. Moreover, these sites likely attract interest due to
suspicion of more diverse and complex microbial communities than elsewhere in the
gastrointestinal tract. It is thought bacteria associated with the intestinal mucosa may
have more important interactions with the host, though unfortunately faecal samples
cannot distinguish these bacteria from non-adherent bacteria simply passing through
from higher in the gastrointestinal tract[142].
Bacterial communities in CF faecal samples from both children and adults appear
to be dependent on CFTR genotype; patients with more severe genotypes harbour
a greater abundance of potentially pathogenic bacteria[143]. In young children with
CF, metagenomic sequencing of faecal microbiota found higher levels of Escherichia
coli compared to healthy age-matched controls, with no specific features of virulence,
suggesting E. coli could be involved in an inflammatory relationship with the host[144].
The community structure of CF faecal microbiota has been determined by DGGE,
revealing CF patients have greater inter-individual variation and greater variation in
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faecal microbiota over time compared to their siblings[145]. Though there is also vast
inter-individual variation in the CF airway microbiome, the fluctuation in composition
of faecal microbiota over time is discordant with the relative stability in the CF airway
microbiome. Since no clinical data is presented in this paper, it is difficult to speculate
on the reasons behind these striking differences, although antibiotic tissue penetration
and biofilm formation in the lungs may play a role in determining the community
structure of these different niches.
A link between gastrointestinal and respiratory microbiomes has been reported in
infants, whereby particular bacterial genera increase in abundance sequentially in the
gastrointestinal tract followed by the respiratory tract, and gaining greater phylogenetic
diversity[104]. It is therefore not surprising that infant gut microbiota is also strongly
associated with mode of delivery[146].
Metagenomic sequencing of faecal microbiota from healthy volunteers reveals peo-
ple can be grouped into enterotypes, which is likely dependent on diet, and this diverse
community may have a significant symbiotic relationship with healthy hosts through di-
gestion of carbohydrates and production of vitamins[147]. In addition, this paper spec-
ulates metabolic processes of bacterial communities in the gastrointestinal tract may
have an effect on health, specifically obesity. Despite efforts to demonstrate acquisition
of a particular enterotype causes obesity in a mouse model[148], it does not demonstrate
a temporal relationship between enterotype and obesity can occur naturally, albeit re-
inforcing the pivotal role of gut microbiota metabolic symbiosis. Clostridium cluster
XIVa has been demonstrated to be the most common mucin-adherent bacterial species
in models of the human gut[149]. Exploring dysbiosis in CF gut, Duytschaever et al.
found CF patients had decreased abundance of Clostridium cluster XIVa, likely due to
antibiotic therapy, and that abundance of this species correlates with patient weight for
height[150]. This demonstrates an association between gut microbiota and nutritional
status in CF, although the underlying reasons have not been elucidated.
Antibiotic exposure is another major extrinsic factor influencing gut microbiota.
In healthy adults given short-term antibiotics, bacterial abundance in faecal samples
declined markedly, though returned to normal following discontinuation of antibiotic
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therapy[151]. The effects of long-term prophylactic antibiotics and additional antibi-
otic therapy administered during exacerbation in cystic fibrosis would therefore have
a pivotal role in the composition of CF gut microbiota. Gut microbiota also has in-
teractions with the host immune system, and in CF there is a reduction in abundance
of Bifidobacterial species, a collection of bacteria involved in maturation of the host
mucosal immune system[150]. This could have far-reaching effects in augmenting lung
inflammation.
Therapeutic interventions to change gut microbiota, such as faecal transplanta-
tion and probiotic products, have received some interest. Recently, a small clinical trial
demonstrated faecal transplant cured 15 of 16 patients with recurrent Clostridium diffi-
cile infection, being significantly more effective than standard treatment[152]. Probiotic
products have largely escaped regulation as pharmaceutical products, although there is
evidence that they may be effective in controlling symptoms in patients with irritable
bowel syndrome, however studies have failed to demonstrate efficacy in inflammatory
bowel disease[142].
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1.17 Aims of this study
The skin microbiome has received no attention in CF, apart from limited studies on
hand hygeine[153, 154]. These studies have demonstrated carriage of CF pathogens
on the hands of CF patients, however did not sample other sites or compare to any
control groups. The CF skin has a higher salt level as evidenced by the role of pilo-
carpine iontophoresis in diagnosis and may harbour a transient pathogenic community.
In addition, given the differences in the CF skin conditions, there may be a different
community structure present. The aims of this study are to:
• Assemble and identify a collection of bacterial and fungal isolates from skin, nare,
and oropharynx from children with CF and healthy controls.
• Optimise DNA extraction methodology for use on swabs from skin, nare, and
oropharynx.
• Characterise the microbiomes of skin, nare, and oropharynx in children with CF
and healthy controls.
Identification and assembly of a collection of bacterial and fungal isolates is under-
taken with the intention of providing a culture-based overview of microbiota on the
skin, nare, and oropharynx of children with CF and healthy controls. These data will
be used to characterise each niche and provide comparison between sites within CF
patients and also comparisons between each niche in CF patients and healthy controls.
Optimisation of DNA extraction for swabs from skin, nare and oropharynx is necessary
to ensure adequate yields and quality for next-generation sequencing given the paucity
of papers describing DNA extraction methods from low biomass environments, for ex-
ample skin.
Examining the microbiome using 16S sequencing of skin, nare, and oropharynx of CF
patients and healthy controls intends to identify to genus level bacteria present in these
niches which, to include bacteria which are difficult to isolate using traditional micro-
bial culture techniques, and provide relative quantity data for each niche. In addition
to culture-based data this could provide further insights into differences between each
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niche in CF patients and healthy controls and any overlap present which may suggest
transmission routes of pathogens. This study intends to study the feasibility of inves-
tigating microbiomes of skin, nare and oropharynx in children with CF and healthy
controls, and may provide potential routes of transmission. Furthermore, these bacte-
rial samples can be assembled to provide a basis for investigation in further studies.
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Chapter 2
Methodology
2.1 Research governance
The study protocol and patient documentation was designed. Research ethics com-
mittee approval was sought from the Liverpool Central National Ethics Committee to
conduct this study and for any subsequent substantial amendment required.
Sponsorship and insurance were sought from the University of Liverpool to conduct
this study and approval sought for any subsequent amendments to the study protocol.
A research passport was sought from the University of Liverpool to collect samples and
clinical data for this study.
Approval from the Research and Development department at Alder Hey Children’s
NHS Trust was sought to conduct the study in their Trust.
Funding applications for the project were made to Alder Hey Children’s Charity and
the University of Liverpool Technology Directorate voucher scheme.
The approval letters from the research ethics committee and the Research and
Development department at Alder Hey Children’s NHS Trust can be found in the
appendix.
2.2 Patient samples
Children with CF 12 years or younger were recruited from the CF clinic and healthy
age and sex matched subjects were recruited from the surgical clinic at Alder Hey
Children’s NHS Trust. Subjects were sex and age-matched within two years. This is to
ensure that the development of the microbiome of each subject is comparable during
analysis.
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Clear inclusion and exclusion criteria were set as follows for both groups.
Inclusion:
1. 12 years or younger
2. In the CF group only: diagnosis of CF confirmed by genotype
Exclusion:
1. Significant concomitant medical condition unrelated to CF
2. Antimicrobials taken within the past month (in addition to any anti-staphylococcal
prophylaxis for the CF group).
3. Viral illness within past month.
4. Atopic eczema or other skin condition affecting sampling areas
Two swabs were taken from each site on each subject; one Catch-All swab (MoBio)
followed by one culture swab in Amies media (Sterillin). Sites swabs were taken from:
1. Entire forearm and hand or only antecubital fossa.
2. Both axillae (same swab)
3. Both nares (same swab)
4. Oropharynx
Entire forearm swabs were performed in a uniform manner, with the swab (for both
culture and culture-independent analysis) immersed in sterile distilled water (SDW),
and rubbed vigorously along each surface of the forearm five times before rotating the
swab 90◦. After covering the forearm and the dorsal side of the hand in this manner, the
palmar surface of the hand was rubbed five times in addition to the interdigital spaces.
The dominant hand and arm was swabbed first, followed by the non-dominant hand
and arm with the same swab. In all further chapters, swabs from hand and forearm
will be referred to as ”forearm” intended to mean inclusion of hand as well.
Swabs from the antecubital fossa were performed in a uniform manner whereby the
swab (for both culture and culture-independent analysis) was immersed in SDW and
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rubbed across the antecubital fossa (inner elbow) vigorously ten times and then rotated
90◦, and this repeated four times across this area.
Nasal swabs were taken with a dry swab whereby the swab was rubbed on the inside
of the left anterior nare ten times, followed by the right anterior nare ten times. This
was performed for both culture swab and culture-independent swab.
Oropharyngeal swabs were taken by inserting the swab into the mouth of the sub-
ject, asking the subject to cough and then as they cough, rubbing the swab along the
soft palate including the oropharynx. This was performed for both the culture swab
and culture-independent swab. This was a pragmatic sampling method chosen to en-
able sampling of small children and infants in the same manner as the older subjects
where it is not possible to gain a pure cough swab and to enable greater bacterial yields.
Although further sampling from the groin for example would have been desirable,
particularly to detect S. aureus, this was balanced against the dignity of subjects and
their likely willingness to partake in the study. In addition, it would have been desirable
to use more vigorous methods to collect skin samples, for example scraping or rubbing
skin with a sterile brush though this also had to be weighed against subject discomfort
and their willingness to participate in the study.
For all swabs, great care was taken to avoid contamination (gloves were worn, swabs
were only removed from packaging immediately prior to sample collection, and care was
taken to avoid contact with and other surface). The culture-dependent swabs were cut
dry into small sterile autoclaved tubes with sterile disposable scissors (Instrapac) imme-
diately after collection while culture swabs were placed directly into the Amies media.
All swabs were transported to the laboratory within four hours and culture-independent
swabs frozen in the tubes at -20◦C immediately on arrival. This is in line with pub-
lished work finding storage at room temperature for prolonged periods makes negligible
differences to sample integrity and microbial community structure[155]. Culture swabs
were inoculated into media within 18 hours.
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2.3 Patient data
Patient data collected included CFTR genotype, clinical state at sampling (stable or
exacerbation), previous medical history, drugs currently taken by patients at the time
of sampling, and hygiene routines.
Data collected from healthy controls included any previous medical history, and
hygiene routines.
All data collected was current at time of sampling, however the ethical approval
included the possibility to record elements of medical history from case notes during
the study period (initially set at two years) but after sampling.
2.4 DNA extraction
DNA extraction prior to library preparation was carried out using MoBio Ultraclean
DNA Isolation kit, according to the manufacturer’s instructions with the following
deviations from the protocol:
1. Catch-All swab was incubated for 18 hours at 37◦C, shaking at 300rpm, in a
1.5mL Eppendorf tube with 300µL Microbead solution (MoBio) and 4µL Ready-
Lyse Lysosyme (Epicentre).
2. Contents of the Eppendorf, including the swab, was transferred to the MoBio
beadtube.
3. Following addition of MD1 solution (MoBio), the beadtube was subject to heating
at 70◦C for 10 minutes followed by beadbeating (MP Bio) at 6.5 m/s for 30s twice
with a 5 minute interval on ice between each cycle.
4. Elution of DNA was performed in DEPC water (Ambion) and water left in the
spin column for ten minutes prior to centrifugation. The elute was then placed
back into the spin column and left for a further ten minutes prior to a second
centrifugation step at 10,000G.
Other DNA extraction kits used in optimisation were PowerSoil DNA Isolation kit
(MoBio), BiOstic Bacteremia kit (MoBio), and QIAmp DNA minikit (Qiagen). Any
deviations from the manufacturer’s protocol are stated.
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2.5 DNA concentration methods
DNA concentration was performed with three methods (Ampure magnetic beads, ethanol
precipitation, and vacuum method) for optimisation, after which a vacuum method was
decided upon, using the SpeedVac.
2.5.1 Ampure XP beads
100µL (1:1 ratio by volume) of Ampure XP magnetic beads (Beckman) were added to
the sample which was then vortexed briefly and incubated for 10 minutes. The tube
was then placed in a magnetic rack and left for 5 minutes for the DNA to bind to
the magnetic beads. The supernatant was then removed and the beads eluted in 13µL
DEPC water (Ambion). This was vortexed briefly and left for the DNA to elute in
the smaller volume for 5 minutes. The tube is then returned to the magnetic rack and
supernatant of water with DNA eluted removed.
2.5.2 Ethanol precipitation
10µL (1:10 ratio by volume) of sodium acetate (Sigma) were added to the DNA elute,
followed by addition of 300µL of 100% molecular grade ethanol (Sigma). This was incu-
bated for 18 hours at -20◦C, followed by centrifugation at 15000G at room temperature
for 15 minutes. The supernatant was then discarded and the remaining pellet washed
with 70% molecular grade ethanol (Sigma), before centrifugation at 15000G at room
temperature for 15 minutes. The supernatant was then discarded and pellet eluted in
13µL DEPC water (Ambion).
2.5.3 Vacuum
Tubes with DNA eluted in water were placed into the SpeedVac machine for 1-2 hour
on medium setting and left for water to evaporate. Following this, the DNA is eluted
in 13µL DEPC water (Ambion) and left for 18-24 hours at 4◦C.
2.6 Library preparation
Miseq dual index amplicon library preparation was performed according to the Illumina
preparation protocol, as follows:
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1. First PCR (adaptors)
2. Clean up with magnetic beads
3. Second PCR (barcodes)
4. Clean up with magnetic beads
5. Library assessment
2.6.1 PCR
PCR was carried out on the Rotogene 6000 qPCR machine (Corbett Life Science),
according to the protocol and conditions specified below. The primers used for the
first adaptor PCR are listed in Table 2.2. The forward barcode primers are listed in
Table 2.3. The reverse barcode primers are listed in Table 2.4.
• 1µL Forward primer
• 1µL Reverse primer
• 12.5µL NEB-Next High Fidelity 2× Master Mix(New England Biolabs)
• 10.5µL Sample including up to 5ng DNA with DEPC water (Ambion) to complete
volume
Cycling conditions were as follows:
Stage Temperature (◦C) Time (s)
Denaturation 95 120
Denaturation 98 20
Annealing 60 15
Elongation 72 40
Elongation 72 60
Table 2.1: Cycling conditions for both PCR cycles in library preparation. The first
PCR ran for 10 cycles while the second ran for 15 samples
Name Forward N5 N5 V4 region annealing site
N5 DR Knight515 CTACACTCTTTCCCTACACGACGCTCTTCCGATCT NNNNN GTGCCAGCMGCCGCCGTAA
DRknight806rev GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT GACTACHVGGGTWTCTAAT
Table 2.2: The above Illumina adaptor -N5 forward and reverse primers were used for
the first PCR
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Name 5’ adaptor i5 index Pad/linker
DI N501For ATTGATACGGCGACCACCGAGATCTACAC TAGATCGC ACACTCTTTCCCTACACGACG
DI N502For ATTGATACGGCGACCACCGAGATCTACAC CTCTCTAT ACACTCTTTCCCTACACGACG
DI N503For ATTGATACGGCGACCACCGAGATCTACAC TATCCTCT ACACTCTTTCCCTACACGACG
DI N504For ATTGATACGGCGACCACCGAGATCTACAC AGAGTAGA ACACTCTTTCCCTACACGACG
DI 505For ATTGATACGGCGACCACCGAGATCTACAC GTAAGGAG ACACTCTTTCCCTACACGACG
DI N506For ATTGATACGGCGACCACCGAGATCTACAC ACTGCATA ACACTCTTTCCCTACACGACG
DI N507For ATTGATACGGCGACCACCGAGATCTACAC AAGGAGTA ACACTCTTTCCCTACACGACG
DI N508For ATTGATACGGCGACCACCGAGATCTACAC CTAAGCCT ACACTCTTTCCCTACACGACG
Table 2.3: List of forward barcode primers for second PCR in library preparation
Name 5’ adaptor i5 index Pad/linker
DI N701Rev CAAGCAGAAGACGGCATACGAGAT TCGCCTTA GTGACTGGAGGTCAGACGTGTGCTCTTCCGATCT
DI N702Rev CAAGCAGAAGACGGCATACGAGAT CTAGTACG GTGACTGGAGGTCAGACGTGTGCTCTTCCGATCT
DI N703Rev CAAGCAGAAGACGGCATACGAGAT TTCTGCCT GTGACTGGAGGTCAGACGTGTGCTCTTCCGATCT
DI N704Rev CAAGCAGAAGACGGCATACGAGAT GCTCAGGA GTGACTGGAGGTCAGACGTGTGCTCTTCCGATCT
DI N705Rev CAAGCAGAAGACGGCATACGAGAT AGGAGTCC GTGACTGGAGGTCAGACGTGTGCTCTTCCGATCT
DI N706Rev CAAGCAGAAGACGGCATACGAGAT CATGCCTA GTGACTGGAGGTCAGACGTGTGCTCTTCCGATCT
DI N707Rev CAAGCAGAAGACGGCATACGAGAT GTAGAGAG GTGACTGGAGGTCAGACGTGTGCTCTTCCGATCT
DI N708Rev CAAGCAGAAGACGGCATACGAGAT CCTCTCTG GTGACTGGAGGTCAGACGTGTGCTCTTCCGATCT
DI N709Rev CAAGCAGAAGACGGCATACGAGAT AGCGTAGC GTGACTGGAGGTCAGACGTGTGCTCTTCCGATCT
DI N710Rev CAAGCAGAAGACGGCATACGAGAT CAGCCTCG GTGACTGGAGGTCAGACGTGTGCTCTTCCGATCT
DI N711Rev CAAGCAGAAGACGGCATACGAGAT TGCCTCTT GTGACTGGAGGTCAGACGTGTGCTCTTCCGATCT
DI N712Rev CAAGCAGAAGACGGCATACGAGAT TCCTCTAC GTGACTGGAGGTCAGACGTGTGCTCTTCCGATCT
Table 2.4: Reverse barcode primers for second PCR in library preparation
2.6.2 Clean up with magnetic beads
Clean up was performed on both first and second PCR products using AMPure XP
magnetic beads (Beckman) as follows:
1. 10µL AMPure XP added
2. Vortex and incubate for 10 minutes
3. Place tubes in magnetic rack and wait 5 minutes to bind
4. Remove supernatant
5. Wash beads twice with 80% ethanol
6. Elute in 13µL of DEPC water (Ambion)
7. Place tubes in magnetic rack and wait 5 minutes to bind
8. Transfer supernatant to a new tube
The magnetic beads bind high molecular weight DNA and leave behind small frag-
ments. Smaller fragments can be recovered with decreasing volume ratios of AMPure
XP to PCR product, see Figure 2.1. As such, 0.8µL AMPure: 1µL PCR product was
chosen to capture the amplicon without any small DNA fragments.
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Figure 2.1: AMPure ratio for size selection
The gel demonstrates size of PCR fragments remaining after each volume ratio of
AMPure beads to PCR product (Reproduced with permission from Dr Jonathan Keats,
TGen, Phoenix)
2.6.3 Library assessment
DNA was quantified from individual samples by fluorometry using a Qubit High Sensi-
tivity Assay Kit (Life Technologies). Library assessment was carried out by the Centre
for Genomic Research, University of Liverpool using a Bioanalyzer 2100 (Agilent)
2.7 Culture swab processing
2.7.1 Initial processing
All culture swabs taken in Amies media were initially inoculated onto all of the following
solid media, in this order, within 24 hours:
1. Blood Columbia × 2
2. Pseudomonas-specific (Oxoid)
3. Staphylococcus-specific (Oxoid)
4. Sabouraud-Dextrose (Oxoid)
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One blood Columbia plate was incubated at 37◦C in a microaerophillic environment
for 48 hours. Sabouraud Dextrose plates were incubated at 37◦C for three weeks. All
other media was incubated at 37◦C overnight.
2.7.2 Growth conditions and storage
Unless otherwise stated, all bacterial isolates were grown according to their original
isolation conditions.
When broth media was necessary, LB-Lennox broth was used and incubated at
37◦C overnight shaking at 70-300rpm.
Growth was streaked on the same media to produce single colonies or single colonies
picked from the original plate. Molds were always sampled from the edge of the
mycelium.
Bacterial and fungal isolates were stored at 4◦C on the respective medias for short
term storage. Bacteria and yeasts, segregated based on colony morphology were stored
at -80◦C in 20% LB-glycerol for longterm storage. Molds were stored at 4◦C on
Sabouraud-dextrose slants for longterm storage.
2.7.3 Media
All media was prepared by autoclaving at 121◦C for 15 minutes and stored at 4◦C until
use. Ingredients which cannot be autoclaved due to breakdown at high temperatures
were filtered through syringe filters with a 0.2µm diameter (Appleton Woods) after any
base materials had been autoclaved and cooled.
2.8 Identification of bacteria
2.8.1 Gram stain
Gram stain procedure was applied to all bacterial and yeast isolates. The procedure
used entailed inoculating small quantities of fresh colonies onto a glass slide using a
pipette tip, and smeared in sterile water. Slides were heat fixed by briefly flaming with
a Bunsen burner. Slides were washed with crystal violet for 1 minute, and then gently
washed with tap water. Slides were then immersed in Lugol’s iodine for 1 minute before
being gently washed again with tap water. Slides were counterstained with safranin for
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30 seconds before gently washing with tap water and leaving to dry.
Microscopy was undertaken and Gram stain reaction, shape of cells, size of cells,
and arrangement of cells was noted.
2.8.2 Oxidase testing
A fresh inoculum of each isolate was rubbed with a sterile loop onto oxidase strips and
observed for colour change immediately. A positive reaction was given as an immediate
colour change to dark purple. P. aeruginosa was used as a positive control and S.
aureus (Oxford strain) was used as a negative control.
2.8.3 Catalase testing
A fresh inoculum of each isolate was rubbed on a sterile plastic plate and flooded with
3% hydrogen peroxide (Sigma), and then observed for evidence of catalase immediately.
A positive reaction was given as immediate and widespread effervescence. S. aureus
(Oxford strain) was used as a positive control and Streptococcus pneumoniae as a
negative control.
2.8.4 Haemolysis
Presence of α- and β- haemolysis was noted qualitatively on blood-Columbia media by
spotting 3µL of growth from overnight LB broth cultures in 96 well plates over two
solid media plates. This was performed in duplicate. In the event of any uncertainty
or widespread haemolysis, individual isolates were streaked onto blood Columbia solid
media. α-haemolysis was determined by an olive green halo around colonies in the ab-
sence of pigment secretion on Columbia media. β-haemolysis was given as a transparent
zone of clearance surrounding colonies.
2.8.5 Gelatinase activity
Gelatin solid media was stab innoculated with 3µL of growth from overnight LB broth
cultures in 96 well plates over four solid media plates and incubed for up to one week.
These were checked daily for halos indicative of gelatinase activity. After one week, the
plate was flooded with saturated ammonium sulphate solution to precipitate protein
and reveal subtle gelatinase activity. Gelatinase activity was considered present if a
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transparent halo appeared around the stab site. This was performed in duplicate and
in the case of any discrepency and with any large areas of gelatinase activity disrupting
interpretation repeated on individual plates.
2.8.6 Urease activity
Isolates were incubated overnight in LB broth and 3µL innoculated into 96 well plates
containing solid Christensen’s urea agar. Evidence of slow urease reaction was noted
after 18 hours and final results of urease testing noted after 48 hours. Any change in
the colour of media from yellow to pink or red was considered a positive test. If the
colour change was only in part of the media closest to the bacterial growth, this was
recorded as a slow urease reaction. For each isolate, this was repeated in duplicate
and in the case of any descreptency, individual isolates were streaked onto solid media
plates.
2.8.7 Mannitol salt agar
Isolates were incubated overnight in LB broth and 3µL innoculated into 96 well plates
containing mannitol salt agar (Oxoid). Evidence of any growth and mannitol fermen-
tation noted after 18-24 hours. Mannitol fermentation was considered positive if there
was any colour change in the media from pink to yellow. This was repeated in duplicate
and in the case of any descreptency, individual isolates were streaked onto solid media
plates. S. aureus (Oxford strain) was used as a positive control and P. aeruginosa was
used as a negative control.
2.8.8 Carbohydrate fermentation tests
Carbohydrate broths were prepared with dextrose, maltose, fructose, and lactose with
a phenol red indicator. Carbohydrate broth was alliquoted into 96 well plates and
innoculated with a 5µL loop of overnight growth from Columbia media. These were
incubated at 37◦C overnight. This was performed in duplicate and any discrepancy
was repeated in triplicate. Acid production, indicated by any colour change from pink
broth to yellow, and any deposits in the tubes were noted. Alkalki response was noted
by a change towards a darker red or pink colour. Positive controls used for lactose and
glucose fermentation were Klebsiella pneumonia ATCC 43816 and Escherichia coli K12
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strain. E. coli K12 strain was also used as a positive control for fructose fermentation.
S. aureus (Oxford strain) was used as a positive control for maltose, fructose, and
sucrose. P. aeruginosa PAO-1 was used as a negative control for all fermentation tests.
In addition, blank wells were used as negative controls.
2.8.9 Computational identification
Pibwin[156], a probabilistic algorithm based on published matrices of identification
resulting from biochemical tests was used to identify isolates from biochemical tests.
This was used to provide a consistent approach to identification and to ensure the
power of identification battery used. Scores are given in the appendix of the likelihood
of each identified isolate.
2.9 Statistical analysis
All statistical analysis was carried out in R version 3.10[157]. Comparisons between
continuous distributions first employed the Shapiro-Wilk test[158] to determine deter-
mine normality of the distribution; p<0.05 indicates a likely non-normal distribution.
Comparisons of similarity in normal distributions were undertaken using the Welch
unpaired t-test. In non-normally distributed data, similarity was determined using the
Mann-Whitney U-test. Standard deviation and mean are stated alongside use of these
tests.
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2.10 Microbiome analysis
Initial analysis of microbiome data was conducted by the Centre for Genomic Research,
University of Liverpool. Analysis of sequence data from 16S amplicon sequencing ini-
tially underwent quality filtering using QIIME[159]. This included trimming and re-
moving illumina adaptors and further trimming to remove low quality bases. Sequences
were aligned to produce a readpare that should cover the 250bp V4 region. Sequences
outside of the range 200bp-350bp were excluded as these likely do not represent the
V4 region. Chimeras were then excluded using both reference-based detection (using a
16S database, Greengenes, to find potential chimera sequences which may match) and
de-novo chimera calling. OTU picking was then undertaken using QIIME. After this
stage, we were given the microbiome data as OTU tables for further analysis. This was
carried out in QIIME to produce alpha-diversity statistics using the chao1 measure, a
proxy of the rare species count[159] and all further OTU-based analysis was conducted
in R 3.10[157].
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Chapter 3
Biochemical identification of
isolates
3.1 Introduction
The skin is a complex organ which spans 1.8m2 in the average adult and host to a
diverse microbial community which varies greatly according to topography[160]. The
skin functions to provide defence against infection, a covering to underlying tissue,
temperature regulation, and enables vitamin D synthesis. The skin microbiome varies
greatly according to site, largely due to intrinsic structural differences which create
distinct niches[160]. Intrinsic differences in the structure of skin include density of
glands, presence of hair, and folds due to anatomic site. For example, the axilla provides
a humid, unexposed environment with many apocrine sweat glands. As such, the axilla
is thought to harbour a microbiome of relatively low diversity compared to dry sites such
as the forearm[160]. There is also a difference noted between the ”resident” microbiota
of the skin, indicated by consistent identification of these commensals over time, and
”transient” microbiota of the skin, indicated by inconsistent identification over time in
the same subject[161]. The resident microbiota is largely comprised of Staphylococcus
and Cornynebacteria[162]. The skin microbiome exhibits greater variability over time
compared to other human niches, rendering the transient microbiota of interest as a
potential influencing factor. Although the transient microbiota has not been explored
in great depth[160], there is some evidence that transient species can include pathogens
such as S. aureus, S. pyogenes, and P. aeruginosa[161, 163]. Extrinsic influences on
skin microbiota are wide-ranging, from cosmetics used to exposure to UV light[160]. It
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is clear that there is a great deal of inter-individual variation in skin microbiota and
that there is likely not to be a shared common “healthy microbiome”[71].
Bacterial identification has been carried out using culture-based techniques for over
100 years, which focused on selective isolation of bacterial colonies followed by iden-
tification by staining and biochemical testing for differentiating characteristics of bac-
terial taxonomy[164]. More recently, automated versions of biochemical testing have
been used including strips embedded with many tests specific to a suspected genus or
general testing have been established to streamline the diagnostic microbiology lab-
oratory. A prominent example of this product includes the API system[165]. Mass
spectrometry-based identification[166], matrix-assisted laser desorption/ionization time
of flight (MALDI-TOF), has streamlined the process of identifying bacterial cultures,
however this is not currently a widely used technology outside of large tertiary centres
and does still rely on selective isolation of colonies for culture, meaning overnight incu-
bation of clinical samples. In addition, MALDI-TOF requires a comprehensive database
of reference spectra to accurately identify isolates[167]. More recently, there has been a
move towards next-generation sequencing for diagnostic identification of clinical sam-
ples, and this has been applied liberally to track outbreaks through identification of
single nucleotide polymorphisms in the whole genome sequence[164]. Incorporation of
this technology into diagnostic microbiology would enable culture-independent assess-
ment of clinical samples, however cost is currently prohibitory to employing this in
routine clinical practice.
This chapter aims to provide an overview of the culture-based microbiota present
in CF patients and healthy subjects on a variety of sites at a single time of sampling.
Biochemical identification techniques have been employed as this approach remains the
gold standard for differentiation of bacterial species[63].
38
3.2 Patient characteristics
18 CF patients were recruited in total, all during stable disease. As stated in the
introduction, CF exacerbation can be described as a sudden increase in symptoms[34]
however there is no uniform interpretation of this, so to enable standardised recruitment
in this study, patients who were taking back-up antibiotics were excluded. Subjects 1 to
10 were swabbed from ACF, axilla, nare and oropharynx with both culture swabs and
Catch-All swabs for DNA extraction. Subjects 14 to 18 were swabbed from forearm,
axilla, nare and oropharynx with both culture swabs and Catch-All swabs for DNA
extraction. Subjects 11, 12, and 13 were swabbed from ACF and forearm during
separate clinic visits in addition to axilla, nare and oropharynx using both culture
swabs and Catch-All swabs for DNA extraction. Their characteristics can be seen in
Table 3.1.
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1 M F508del/F508del 4 x x x
2 M F508del/G551D 5 x x
3 M 5F08del/F508del 6
4 M F508del/F508del 9
5 F F508del/F508del 10 x x
6 F F508del/exon 10 duplication 12 x x
7 F F508del/F508del 12 x x
8 F F508del/1154insTC 9 x
9 M F508del/F508del 4 x
10 M F508del/F508del 10 x
11 F F508del/G551D 6 x x x
12 F F508del/3007delG 5 x x x x
13 M F508del/F508del 12 x
14 F F508del/F508del 3 x x x
15 M F508del/F508del 0 *
16 M F508del/F508del 9 x x x
17 M F508del/F508del 3 x x
18 F F508del/F508del 7
36† M F508del/R117H (7T) 0
Table 3.1: CF patients recruited during study period with CFTR genotype, age at sam-
pling and pathogens identified in oropharyngeal swabs or sputum during the previous
year (CF Trust data).
∗ indicates cultured during the previous year, however no annual review has taken
place.
† indicates subject with equivocal diagnosis.
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13 of 18 CF subjects recruited have homozygous F508del CFTR genotype, 2 of
18 CF subjects have F508del/G551D CFTR genotype, one CF subject had F508del
with a large exon 10 duplication, one CF subject had F508del/1154insTC, and one
had F508del/3007delG. All CF patients were taking anti-staphylococcal antibiotic pro-
phylaxis. None of the patients with G551D mutation were taking ivacaftor as part of
treatment. The age of subjects varied between infants (subject 15) and 12 years old
(subjects 6, 7 and 13). Culture results from oropharyngeal swabs and sputum sam-
ples collected in outpatient clinics and hospital in patient stays during the previous
year are displayed. Other significant pathogens cultured include Haemophilus parain-
fluenzae, Streptococcus pyogenes, and Escherichia coli in subject one; Pseudomonas
putida in subject nine; Serratia in subject 11; and Streptococcus pnemoniae and H.
parainfluenzae in subject 12.
17 age-matched healthy controls were recruited from the surgical clinic at Alder Hey
Children’s NHS trust. These patients are all aged within two years of their respective
CF patients for the microbiome study analysis. These controls had often had previous
surgical problems and were followed up in an outpatient clinic so they will have had
contact with the hospital environment prior to being recruited. All healthy control
subjects were swabbed with culture swabs and Catch-All swabs from forearm, axilla,
nare and oropharynx. The differences in swab technique through the study were due
to difficulties with low quantities of DNA from swabs of only ACF during the start of
the study and this was remedied by using the entire forearm including hand.
One patient (subject 36) was recruited with equivocal diagnosis. This infant had
a borderline sweat test following positive newborn screening and was found to have
F508del/R117H with a 7 thymidine repeat, a genotype with variable clinical conse-
quence[168].
Table 3.2 shows a summary of CF patients and age-matched controls. 17 age-
matched healthy controls were recruited including one subject to pair with subject 36,
the patient with equivocal diagnosis.
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Cystic fibrosis group Age-matched healthy controls
Subject ID Sex Age Genotype Subject ID Sex Age Sex-match
1 M 4.12 F508del/F508del
2 M 5.59 F508del/G551D 30 M 6.10 Yes
3 M 6.88 F508del/F508del 33 F 6.27 No
4 M 9.31 F508del/F508del 29 F 8.67 No
5 F 10.02 F508del/F508del 22 F 9.01 Yes
6 F 12.64 F508del/exon 10 duplication 27 M 11.42 No
7 F 12.06 F508del/F508del 35 F 10.34 Yes
8 F 9.06 F508del/1154insTC 34 F 8.25 Yes
9 M 4.35 F508del/3007delG 23 F 5.30 No
10 M 10.74 F508del/F508del 28 F 9.48 No
11 F 6.34 F508del/F508del 21 M 6.19 No
12 F 5.52 F508del/F508del 26 F 5.96 Yes
13 M 12.76 F508del/F508del 24 M 12.60 Yes
14 F 3.84 F508del/F508del
15 M 0.47 F508del/F508del 31 F 0.21 No
16 M 9.12 F508del/F508del 19 M 8.62 Yes
17 M 3.56 F508del/F508del 25 M 4.83 Yes
18 F 7.95 F508del/F508del 20 M 6.35 No
36† M 0.65 F508del/R117H(7T) 32 M 0.30 Yes
Table 3.2: Characteristics of CF patients and their age-matched controls.
† indicates subject with equivocal diagnosis.
41
Table 3.2 shows similar average ages of CF patients and healthy controls, though
slightly younger healthy controls and similar ratios of male:female. There is no signifi-
cant difference of age (t-test, p=0.73) or sex (χ 2, p=0.24).
CF patients Healthy controls
Mean age (SD) 7.46 (3.51) 7.05 (3.37)
Median age 7.41 6.35
% male 55.60% 47.10%
Table 3.3: Summary statistics of subjects in CF and control group.
Data on personal hygiene was gathered from 15 of 18 CF patients and 12 of 17
healthy controls recruited. This information could not be collected from some patients
due to lack of time given pressures of space for clinical work in the outpatient depart-
ment, and was not possible to gain through telephone contact. Table 3.2 demonstrates
similarities between the CF patients and healthy controls recruited for their use of
deodorant and preference for showering or bathing. Frequent use of alcohol gel was
reported in 3 of 18 CF patients and not at all in the control group.
CF patients Healthy controls
Collected 15 (83%) 12 (71%)
Alcohol gel 3 (20%) 0 (0%)
Deodorant 4 (26%) 3 (25%)
Shower 2 (13%) 2 (16%)
Bath 11 (73%) 9 (75%)
Shower/Bath 2 (13%) 1 (8%)
Table 3.4: Summary statistics of CF patients vs healthy controls where data could be
collected on hygeine, proportion using alcohol gel and deodorant.
It also shows the proportions who prefer to shower or bath, and those who bath and
shower equally.
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The frequency of bathing or showering also appears to be higher in CF patients
compared to healthy controls, shown in figure 3.1, however is not statistically signif-
icant (χ=5.63, p=0.34). A similar pattern in shown in frequency of handwashing in
figure 3.2 where although it appears higher in CF patients it is not statistically sig-
nificant (χ=4.24, p=0.37). The categories for handwashing frequency were chosen in
response to difficulty of families interviewed to quantify handwashing, and many re-
sponding with these categories.
Figure 3.1: Frequency of bathing or showering in CF patients recruited compared to
healthy controls.
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Figure 3.2: Frequency of handwashing in CF patients compared to healthy controls.
“Less frequently” refers to less frequently than after toilet or before eating and “more
frequently” refers to more frequently than before eating and after toilet.
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3.3 Results
3.3.1 Bacterial culture results from CF patients
This chapter contains the bacterial culture results from healthy subjects and subjects
with CF. Although many Staphylococcus isolates were identified to species level, all
apart from S. aureus are presented only as the Staphylococcus to ease interpretation.
Moreover, not all isolates from subjects with forearm, axilla, nare, and oropharynx
have been identified given time pressures to complete laboratory work. As such, from
these subjects, only aerobic cultures were identified. A full list of bacterial culture and
biochemical test results can be found in Appendix D.
Table 3.5 shows culture results from ACF, axilla, nare, and oropharynx in CF
patients. Staphylococcus was universally present in all samples. S. aureus was found
in the ACF and axilla of subject 4, and the nare of subject 10.
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1 ACF x
1 Axilla x
1 Nare x
1 Oropharynx x c c c
2 ACF x
2 Axilla x
2 Nare x
2 Oropharynx x c c
3 ACF x
3 Axilla x
3 Nare x
3 Oropharynx x
4 ACF x x
4 Axilla x x
4 Nare x
4 Oropharynx x
5 ACF x
5 Axilla x
5 Nare x
5 Oropharynx x c c
6 ACF x x x
6 Axilla x
6 Nare x x x
6 Oropharynx x x x c c x
6 Sput x c
7 ACF x
7 Axilla x
7 Nare x
7 Oropharynx x c c
8 ACF x
8 Axilla x x
8 Nare x
8 Oropharynx x c
9 ACF x x
9 Axilla x
9 Nare x
9 Oropharynx x c
10 ACF x
10 Axilla x
10 Nare x x x
10 Oropharynx x c
Table 3.5: Bacterial culture results from CF patients swabbed from ACF, axilla, nare
and oropharynx. ”x” indicates isolated on culture during study period while ”c” indi-
cates isolated during a clinic visit in the year prior to the study.
Other significant pathogens included: S. pyogenes, and E. coli isolated from subject one
during a clinic visit; Acinetobacter and Arthrobacter isolated from subject six during
the study period. Subject five was found to have MRSA during a clinic visit.
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14 Forearm x x
14 Axilla x x
14 Nare x
14 Oropharynx x c c c
15 ACF x
15 Axilla x
15 Nare x
15 Oropharynx x
16 Forearm x
16 Axilla x
16 Nare x
16 Oropharynx x x c x c c
17 Forearm x x
17 Axilla x
17 Nare x
17 Oropharynx x c c
18 Forearm x x x
18 Axilla x
18 Nare x
18 Oropharynx x
36* Forearm x
36* Axilla x
36* Nare x
36* Oropharynx x
Table 3.6: Bacterial culture results from CF patients swabbed from entire forearm,
axilla, nare and oropharynx. ”x” indicates isolated on culture during study period
while ”c” indicates isolated during a clinic visit in the year prior to the study.
Other significant pathogens included: Candida isolated from subject 14 during a clinic
visit; M. catarrhalis and MRSA isolated from subject 16 during a clinic visit; and a
coliform isolated from subject 17 during a clinic visit.
∗ indicates patient with equivocal diagnosis.
Table 3.6 shows culture results from the entire forearm, nare, and oropharynx of
CF patients. This distribution of results does not differ greatly from those obtained
from just the ACF, and it is clear that Staphylococcus is present in all the samples. P.
aeruginosa was isolated from the oropharynx of patient 16 during the study and on
culture during clinic visits in the year prior to the study. Of note, Pseudomonas was
isolated from the forearm of subject 18, who had no growth of respiratory pathogens
from oropharyngeal swabs in the previous year.
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11(1) ACF x x
11(1) Axilla x x
11(1) Nare x
11(1) Oropharynx x c x c c
11(2) Forearm x
11(2) Axilla x
11(2) Nare x
11(2) Oropharynx x c c c
12(1) ACF x
12(1) Axilla x
12(1) Nare x
12(1) Oropharynx x c c c c
12(2) Forearm x
12(2) Axilla x x
12(2) Nare x x x
12(2) Oropharynx x c c c c
13(1) ACF x
13(1) Axilla x
13(1) Nare x
13(1) Oropharynx x x c
13(2) Forearm x x
13(2) Axilla x
13(2) Nare x x
13(2) Oropharynx x x c
Table 3.7: Bacterial culture results from CF patients swabbed from ACF and entire
forearm at separate clinic visits, in addition to axilla, nare and oropharynx. ”x” in-
dicates isolated on culture during study period while ”c” indicates isolated during a
clinic visit in the year prior to the study.
Other significant pathogens included: Serratia isolated from subject 11 during a clinic
visit and S. pneumoniae isolated from subject 12 during a clinic visit.
Table 3.7 shows culture results obtained from patients initially recruited with swabs
of only ACF of the arm taken in addition to axilla, nare and oropharyngeal swabs, and
then seen in a further clinic visit with forearm swabs taken in addition to another set of
axilla, nare and oropharyngeal swabs. Although subject 11 had cultured P. aeruginosa
in the previous year, this was not detected on the oropharyngeal swabs obtained during
the study. In addition, subject 11 was initially found to have S. aureus in the axilla
and Streptococcus in the oropharynx but neither were isolated at a later date. Subject
12 had cultured P. aeruginosa during the previous year, and although this was not
cultured in the oropharynx during the study visit, Pseudomonas was found in the nare
the second time this subject was swabbed in addition to S. aureus in the axilla and
nare which was absent during the first visit. Subject 13 had cultured P. aeruginosa
during the previous year and had no growth of Pseudomonas from any site during the
first study visit, but on the second visit Pseudomonas was found on the forearm, nare,
and oropharynx.
48
3.3.2 Bacterial culture results from healthy subjects
Tables 3.8 and 3.9 demonstrate culture results obtained from healthy subjects where
the skin swabs are from the ACF and forearm, respectively, and both sets with axilla,
nare, and oropharynx. Three healthy controls overall were found to have Pseudomonas
colonisation (see table 3.9): Subject 22 was found to be colonised in the ACF, axilla
and nare; Subject 25 was found to be colonised in the axilla, nare and oropharynx; and
subject 26 was found to be colonised in the axilla only. Subject 20 was found to be
colonised with Streptococcus in the axilla and nare, while subject 26 was found to be
colonised with Acinetobacter in addition to Pseudomonas in the axilla.
Interestingly, similar proportions of CF patients and healthy controls were found to
be colonised with Pseudomonas during the study period; 5 of 18 CF subjects compared
to 3 of 17 healthy controls. The subject with equivocal diagnosis was only found to be
colonised with Staphylococcus at all sites.
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14 Forearm x x
14 Axilla x x
14 Nare x
14 Oropharynx x
15 Forearm x
15 Axilla x
15 Nare x
15 Oropharynx x
16 Forearm x
16 Axilla x
16 Nare x
16 Oropharynx x x x
17 Forearm x x
17 Axilla x
17 Nare x
17 Oropharynx x
18 Forearm x x x
18 Axilla x
18 Nare x
18 Oropharynx x
19 ACF x
19 Axilla x
19 Nare x
19 Oropharynx x
20 ACF x
20 Axilla x x
20 Nare x x x
20 Oropharynx x
21 ACF x
21 Axilla x x
21 Nare x
21 Oropharynx x x
22 ACF x x x
22 Axilla x x x
22 Nare x x x
22 Oropharynx x
23 ACF x
23 Axilla x
23 Nare x
23 Oropharynx x
24 ACF x
24 Axilla x
24 Nare x
24 Oropharynx x
25 ACF x x
25 Axilla x x
25 Nare x x x
25 Oropharynx x x x
26 ACF x
26 Axilla x x x
26 Nare x x
26 Oropharynx x x
27 ACF x
27 Axilla x
27 Nare x
27 Oropharynx x
Table 3.8: Bacterial culture results from healthy subjects swabbed from ACF, axilla,
nare and oropharynx. ”x” indicates isolated on culture during study period.
Other significant results included: Streptococcus from subject 20 in the axilla and nare
and Acinetobacter from the axilla of subject 26 during the study period.
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28 Forearm x
28 Axilla x x
28 Nare x
28 Oropharynx x
29 Forearm x
29 Axilla x
29 Nare x
29 Oropharynx x
30 Forearm x
30 Axilla x
30 Nare x
30 Oropharynx x
31 Forearm x
31 Axilla x
31 Nare x
31 Oropharynx x
32 Forearm x x
32 Axilla x
32 Nare x
32 Oropharynx x
33 Forearm x
33 Axilla x
33 Nare x
33 Oropharynx x
34 Forearm x x
34 Axilla x
34 Nare x
34 Oropharynx x
35 Forearm x
35 Axilla x
35 Nare x
35 Oropharynx x
36 Forearm x
36 Axilla x
36 Nare x
36 Oropharynx x
Table 3.9: Bacterial culture results from healthy subjects swabbed from entire forearm,
axilla, nare and oropharynx. ”x” indicates isolated on culture during study period.
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3.3.3 Culture results by anatomic site
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1 Y x
2 Y x
3 Y x
4 Y x x
5 Y x
6 Y x x x
7 Y x
8 Y x
9 Y x x
10 Y x
11(1) Y x x
12(1) Y x
13(1) Y x
19 N x
20 N x
21 N x
22 N x x x
23 N x
24 N x
25 N x x
26 N x
27 N x
Table 3.10: Bacterial culture results from the ACF of both CF patients and healthy
controls. ”x” indicates isolated on culture during study period. (1) indicates the isolates
were obtained during the first study visit of these subjects.
Bacterial culture results from only the ACF (see table 3.10) indicate a slight increase
in Streptococcus colonisation in CF patients compared to healthy controls (2 of 13
CF subjects compared to 0 of 13 healthy subjects). However, the only Pseudomonas
colonisation was found to be in one healthy subject.
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1 Y x
2 Y x
3 Y x
4 Y x x
5 Y x
6 Y x
7 Y x
8 Y x x
9 Y x
10 Y x
11(1) Y x x
11(2) Y x
12(1) Y x
12(2) Y x x
13(1) Y x
13(2) Y x
14 Y x x
15 Y x
16 Y x
17 Y x
18 Y x
19 N x
20 N x x
21 N x x
22 N x x x
23 N x
24 N x
25 N x x
26 N x x x
27 N x
28 N x x
29 N x
30 N x
31 N x
32 N x
33 N x
34 N x
35 N x
36 N x
Table 3.11: Bacterial culture results from the axilla of both CF patients and healthy
controls. ”x” indicates isolated on culture during study period. (1) indicates the iso-
lates were obtained during the first study visit while (2) indicates the isolates were
obtained during the second study visit.
Other results found include Streptococcus from subject 20 and Acinetobacter from sub-
ject 26.
Bacterial culture results from only the axilla (see table 3.11) indicate distinct dif-
ferences between colonisation of the CF subjects and healthy subjects. S. aureus is
only seen in the CF subjects, and in observing subjects 11, 12, and 13 where sequential
samples were obtained, it does not appear to be constantly present in the samples.
Pseudomonas is only found in the axilla of healthy subjects in this study, and in addi-
tion Acinetobacter and Streptococcus were isolated from the axilla of healthy subjects.
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Bacterial culture results from the nare (see table 3.12) indicate marked differences
between CF and healthy subjects. Like in the axilla, S. aureus is only present in the
CF subjects and in the subjects with sequential samples (subjects 11, 12, and 13),
was not present in both. Pseudomonas was present in both CF subjects and healthy
controls, and like S. aureus, was not seen on both occasions where sequential isolates
were obtained. Streptococcus was seen in one subject in each group. There appears to
be a slightly higher proportion of healthy subjects who have nasal colonisation with
Micrococcus compared to CF subjects (4 of 17 compared to 1 of 18).
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1 Y x
2 Y x
3 Y x
4 Y x
5 Y x
6 Y x x x
7 Y x
8 Y x
9 Y x
10 Y x x x
11(1) Y x
11(2) Y x
12(1) Y x
12(2) Y x x x
13(1) Y x
13(2) Y x x
14 Y x
15 Y x
16 Y x
17 Y x
18 Y x
19 N x
20 N x x x
21 N x
22 N x x x
23 N x
24 N x
25 N x x x
26 N x x
27 N x
28 N x
29 N x
30 N x
31 N x
32 N x
33 N x
34 N x
35 N x
36 N x
Table 3.12: Bacterial culture results from nares of both CF patients and healthy con-
trols. ”x” indicates isolated on culture during study period. (1) indicates the isolates
were obtained during the first study visit while (2) indicates the isolates were obtained
during the second study visit.
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Bacterial culture results from the forearm (see table 3.13) demonstrated carriage of
potential pathogens only in CF patients. S. aureus was isolated from subject 14, while
Pseudomonas was isolated from subject 13 on the second study visit and subject 18.
Bacterial culture results from oropharyngeal swabs and sputum samples of CF sub-
jects and healthy controls (see table 3.14 demonstrate colonisation with Pseudomonas
in two subjects with CF and two healthy subjects. In subject 6, Pseudomonas was
cultured from both the oropharyngeal swab and a sputum sample and subject 13 was
found to have Pseudomonas following the second study visit but not the first. In addi-
tion to colonisation with Pseudomonas, subject 6 was found to have Acinetobacter and
Arthrobacter. Subject 11 was found to have Streptococcus colonisation during the first
study visit but not the second.
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11(2) Y x
12(2) Y x
13(2) Y x x
14 Y x x
15 Y x
16 Y x
17 Y x x
18 Y x x x
28 N x
29 N x
30 N x
31 N x
32 N x x
33 N x
34 N x x
35 N x
36 N x
Table 3.13: Bacterial culture results from forearms of both CF patients and healthy
controls. ”x” indicates isolated on culture during study period. (2) indicates the isolates
were obtained during the first study visit from these subjects.
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1 Y x
2 Y x
3 Y x
4 Y x
5 Y x
6 Y x x x x
6* Y x
7 Y x
8 Y x
9 Y x
10 Y x
11(1) Y x x
11(2) Y x
12(1) Y x
12(2) Y x
13(1) Y x x
13(2) Y x x
14 N x
15 N x
16 N x x x
17 N x
18 N x
19 N x
20 N x
21 N x x
22 N x
23 N x
24 N x
25 N x x x
26 N x x
27 N x
28 N x
29 N x
30 N x
31 N x
32 N x
33 N x
34 N x
35 N x
36 N x
Table 3.14: Bacterial culture results from the oropharynx and sputum of both CF
patients and healthy controls. ”x” indicates isolated on culture during study period.
(1) indicates the isolates were obtained during the first study visit while (2) indicates
the isolates were obtained during the second study visit.
Other significant results include Acinetobacter and Arthrobacter in the oropharyngeal
swab of subject six, and Streptococcus from the first study visit of subject 11.
∗ indicates sputum sample.
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3.3.4 Overall summary of bacterial culture results
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Figure 3.3: 100% stacked bar chart demonstrating the proportion of culture results by
site in both CF and healthy subjects. This data includes sequential samples from the
same patients.
Figure 3.3 demonstrates the differences between commensals isolated in CF and
healthy subject sites. Although there appears to be a general background of Staphylo-
coccus and Micrococcus, there appears to be some differences between CF and healthy
subjects for those genera isolated less frequently. There were significant differences be-
tween CF patients and healthy controls in the axilla (χ=7.98, p=0.02) but not in ACF
(χ=3.67, p=0.45), nare (χ=3.95, p=0.27), forearm (χ=2.92, p=0.40), or respiratory
samples (χ=1.70, p=0.43).
Interestingly,S. aureus was isolated from the skin and nares of some CF patients
in this study but not from any healthy controls. S. aureus was not isolated from the
oropharynx or sputum of any subject in this study.
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3.4 Discussion
This study has demonstrated a very similar microbiota between healthy children and
children with CF, both demonstrating transient colonisation with potential pathogens.
All sites were shown to be similar between groups apart from the axilla, however these
findings should be viewed with caution given the low sample numbers used in these
Chi-squared tests. This study demonstrated some CF patients carried S. aureus on
their skin and nare whereas no healthy controls did. Given that this population of CF
patients is constantly being treated with S. aureus antibiotic prophylaxis, this finding
merits further investigation. Unfortunately due to the high cost of rabbit plasma the
gold-standard test for S. aureus, the tube coagulase test[169], could not be used and
S. aureus was presumptively identified by microscopy and other biochemical methods.
This limits the specificity of identification and could mean some mannitol-fermenting
Gram-positive cocci identified in the CF population might not be S. aureus. Larger
numbers of participants and more appropriate methods for identification of S. aureus
would be needed to confirm this potentially important finding.
It has been generally accepted that pathogens transiently colonise human skin[161],
and that direct contact between CF patients is the most likely route of transmis-
sion[170]. However, these views are only given as a result of culture-based studies
on bacteria isolated from the hands of CF patients without any healthy controls[153,
154]. This study demonstrates that not only is Pseudomonas sometimes present alone
in skin sites such as the axilla, without being present on the hands, but also that a very
similar pattern is seen in healthy children which has not been demonstrated previously.
It is clear from this study that in the few subjects where sequential isolates were taken,
these are transient microbiota as they are not always present in the same site, however
a much greater sample size would be needed to determine this with certainty.
This study could not accurately identify many isolates to species level, detracting
from the ability to accurately determine the commensal bacteria of CF patients and
healthy controls on culture. Moreover, it is clear from inspection of the biochemical
tests that many more isolates than suspected by the probabalistic model (Pibwin) are
likely to be S. aureus (only identified to their genus), as evidenced by Gram-positive
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fermenting cocci which turn the phenol-red indicator in mannitol salt agar yellow. In
addition, identification matrices do not take into all common indicators, for example,
colony morphology and haemolysis were not included. These are clear disadvantage
of using a computational model based on published matrices, however it does detect
that the culture-based biochemical tests undertaken for identification are likely to be
underpowered and that further tests are necessary for species level identification.
This approach, however, may be useful in identifying a representative number of
suspected pathogens which could be further identified and characterised for this study
and does enable a consistent approach to be taken across all isolates. A more compre-
hensive approach to biochemical testing for this study would have been too burdensome
given the number of samples and of limited value in providing conclusions about the
skin microbiota given that culture-based studies underestimate the bacterial diversity
present[160]. The benefits of limited identification, does however allow for putative
identification of pathogens and builds a large collection of strains for further character-
isation.
This study made use of selective media (Pseudomonas-specific and Staphylococcus-
specific) which increases the sensitivity of culture-based studies in identifying pathogens[171],
and also eased identification of cultures likely to be P. aeruginosa.
Definitions of species still largely revolve around biochemical tests to differentiate
from other similar genera[63], and as such the biochemical approach to bacterial iden-
tification still remains the gold standard compared to newer high-throughput methods,
such as mass spectroscopy-based methods[166]. In addition for a large number of sam-
ples such as this, it is possible to undertake a large number of biochemical tests simul-
taneously using 96 well plates. An issue in doing so is the propensity for contamination,
especially with spore-forming bacteria, when compared to performing biochemical tests
in Durham tubes, for example. The issues of contamination, can however be controlled
with blank wells as a negative control. In addition, this method of testing still remains
more cost-effective compared to use of biochemical test strips, such as the API system,
or MALDI-TOF for a large number of samples where only putative identification of
pathogens is necessary.
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MALDI-TOF could form part of further work to fully characterise these strains but
unfortunately the local facility was prohibitively expensive for this study. If it were
available it would be the preferred method for performing high-throughput identifica-
tion of bacterial cultures. Due to the high proportion of commensals, however it would
be necessary to ensure the reference spectra include the expected skin flora for accu-
rate identification[167] as pathogens would be expected to comprise the predominant
fraction of the reference database. Studies on fungal isolates were not completed, and
this would form part of later work to fully characterise the entire microbial landscape
of CF skin, in addition to further work examining the characteristics of the bacterial
isolates, not only to identify them but demonstrate any differences in behaviour. Bac-
terial characteristics of interest would include quorum sensing to determine how they
are acting in the community[172], antibiotic resistance profiling, and virulence deter-
mination using a high-throughout model such as Galleria[173] to determine if there are
differences between pathogens isolated in different sites, a marker of evolution within
the host[174].
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Chapter 4
Optimisation of DNA extraction
from swabs
4.1 Introduction
Bacterial DNA extraction protocols can be broadly split into those that employ a kit,
those that use buffers which can be prepared in any laboratory, and those that employ
a phenol-chloroform method. Due to thick cell wells, particularly of Gram-positive
bacteria, extraction of DNA from bacteria often requires enzymatic and mechanical
disruption[175].
In microbiome studies, a significant degree of bias can be introduced during the
DNA extraction as this can influence the community composition markedly. There
are many commercial kits available for DNA extraction, each using a slightly different
method which can impact on community composition, and as such, it is important to
use the same kit throughout the study[175]. In addition, commercial kits often have a
microbiome of their own which means it is important to have negative controls included
in the sequencing run[176]. Even if negative controls are included, it is not clear how
best to handle this data in the analysis; although those taxa appearing in the kits
could be excluded from the samples, the bacterial sequences detected in the kit are
likely to be ubiquitous in the environment as well. Phenol-chloroform methods do not
suffer this issue since phenol is a harsh environment for bacteria to survive, however
any DEPC water used downstream can also carry contaminants. Beadbeating is a
mechanical process whereby the sample is placed in a tube with small beads in, which
is then shaken vigorously by a beadmill, a device designed to perform beadbeating.
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Beadbeating leads to better representation of the community structure of microbiomes
and improves yield through greater disruption of cell walls, however it has been criticised
for increasing shearing of DNA, which can be reduced by beadbeating for shorter time
periods[175]. As such, beadbeating is included in the DNA extraction.
Skin microbiota is notoriously difficult to extract DNA from[160], and as such
optomisation of the method is necessary. Through quantitative culture, it has been
demonstrated that moist areas of skin, such as the axilla, have a higher bacterial load
compared to dry areas, such as the volar forearm[160]. This suggests that the lowest
DNA yields in this study will be from the ACF and forearm.
This chapter aims to determine the most appropriate method for DNA extraction
from swabs of different skin sites, nare, and oropharynx, so that results of amplicon
sequencing are deemed comparable. Swabs tested were obtained from healthy adults
within the laboratory group. All comparisons were made between groups with at least
three swabs from each. It will determine a balanced protocol between yields given
from each kit and deviations from the kit protocols investigated for each site to enable
pooling of these samples. Only commercial kits are used in this study due to safety
issues surrounding use of phenol-chloroform methods.
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4.2 Results
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DNA extracted from ACF swabs
Figure 4.1: Comparison of DNA extraction kits, swab types and swab moisening
reagents on DNA yields from swabs of antecubital fossa.
Comparison includes Catch-All in PBS (MoBio Ultraclean) (n=3, mean
(µ)=0.008ng/µL, standard deviation (σ)=0.007), Catch-All in PBS (Qiagen)
(n=6, µ=0.022ng/µL, σ=0.034), Catch-All in SDW (MoBio Ultraclean) (n=3,
µ=0.009ng/µL, σ=0.015), Catch-All in TE-Tween-20 (Qiagen) (n=3, µ=0.015ng/µL,
σ=0.013), and Cotton in PBS (Qiagen) (n=5, µ=0.013ng/µL, σ=0.030).
Qiagen refers to QIAamp DNA minikit.
MoBio Ultraclean refers to MoBio Ultraclean Microbial DNA Isolation kit.
Figure 4.1 demonstrates differences in DNA quantity yielded from different kits
using different buffers to moisten the swabs prior to rubbing on the skin. After each
swab is obtained, the manufacturer’s instructions as per the kit (for the Qiagen QIAamp
kit, the Tissue protocol was followed) were followed with all additional steps suggested
in the manufacturer’s protocol which increase DNA yields.
Although figure 4.1 demonstrates some samples using Catch-All swabs moistened
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with PBS in the Qiagen kit gained some of the highest DNA yields, the majority
of these samples yielded DNA quantities beneath the detectable range (66.6%, n=6).
33.3% (n=3) of Catch-All swabs moisened with PBS in the MoBio Ultraclean kit were
beneath detectable range. 66% (n=3) of Catch-All swabs moisened in SDW in the
MoBio Ultraclean kit had were beneath detectable range. 33.3% (n=3) of Catch-All
swabs moisened in TE-Tween-20 buffer and processed in the Qiagen kit were beneath
detectable range, and 80% (n=5) of cotton swabs in PBS processed in the Qiagen
kit were beneath detectable range of DNA. There are no significant differences in this
comparison (Mann-Whitney U-test: W=8, p=0.888 between distributions with greatest
differences in mean).
As such, it appears that the two approaches which give provide a balance between
DNA yield and reproducibility for extracting DNA from ACF swabs are Catch-All
swabs moistened in PBS using the MoBio Ultraclean Microbial DNA Isolation kit and
Catch-All swabs moistened in TE-Tween-20 using the Qiagen QIAamp DNA Extraction
kit.
Figure 4.2 demonstrates differences in DNA yields between different moistening
agents and swab types for DNA extraction of axilla swabs with a Qiagen QIAamp kit
following the Tissue protocol otherwise. It appears that the most acceptable yields
are obtained from Catch-All swabs moistened in PBS or TE-Tween-20, however the
plot of Catch-All swab moistened with TE is skewed by one data point; 66.6% (n=3)
had DNA yield below detectable limits. Only 20% (n=5) of Catch-All swab in PBS
were beneath detectable DNA limits. 66.6% (n=3) cotton swabs moistened with PBS
were beneath detectable limits and 100% (n=3) of cotton moistened with TE-Tween
were beneath detectable limits. There were significant differences between Catch-All
swabs in PBS (Qiagen) and both cotton in PBS (Qiagen) and cotton in TE-Tween-20
(Qiagen) (Student t-test: t=-3.58, p=0.016 and t=-2.58, p=0.036 respectively) but not
Catch-All in TE-Tween (Qiagen) (Student t-test: t=-0.394, p=0.723).This suggests
that for swabs from the axilla, Catch-All swabs moistened with PBS give the most
acceptable results when using the Qiagen QiaAMP kit.
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Figure 4.2: Comparison of swab types and swab moisening reagents on DNA yields
from axilla swabs.
Comparison includes Catch-All in PBS (Qiagen) (n=5, µ=0.066ng/µL, σ=0.045),
Catch-All in TE-Tween-20 (Qiagen) (n=3, µ=0.046ng/µL, σ=0.080), Cotton in PBS
(Qiagen) (n=3, µ=0.011ng/µL, σ=0.019), and Cotton in TE-Tween-20 (Qiagen) (n=3,
µ=0ng/µL, σ=0).
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Figure 4.3: Comparison of DNA extraction kits and swab types on DNA yields for
nare swabs.
Comparison includes Catch-All in PBS (Qiagen) (n=3, µ=0.154ng/µL, σ=0.090),
Catch-All in TE-Tween-20 (Qiagen) (n=3, µ=0.127ng/µL, σ=0.015), Catch-All dry
(Qiagen) (n=6, µ=1.61ng/µL, σ=1.91), and Cotton dry (Qiagen) (n=2, µ=7.35ng/µL,
σ=9.12).
Figure 4.3 demonstrates differences in DNA yields between different moistening
agents and swab types for DNA extraction of nare swabs with a Qiagen QiaAMP kit
following the Tissue protocol otherwise. There were no significant differences between
this comparison (Mann-Whitney U-test: W=9, p=0.0765 between distributions with
greatest differences in mean) although there is a trend to suggest that the most accept-
able yields are obtained from the dry cotton and Catch-All swabs, compared to using
a moistening agent for the nare. All swab samples tested had DNA levels above the
67
detectable range. Samples from the nare gave higher DNA yields compared to the skin
swabs, with no issues of variability.
Figure 4.4 demonstrates differences in DNA yields between different swab types and
DNA extraction kits for oropharyngeal swabs. 40% (n=5) of Catch-All swabs using the
MoBio Ultraclean kit had undetectable levels of DNA, 11.1% (n=9) of Catch-All swabs
using the Qiagen kit had undetectable levels of DNA, 0% (n=3) of the cotton swabs
using MoBio Ultraclean kit had undetectable DNA levels, and 0% (n=3) of cotton
swabs using the Qiagen kit had undetectable DNA levels. Catch-All (Qiagen) had a
significantly higher yield than Catch-All (MoBio Ultraclean) (Mann-Whitney U-test:
W=44.5, p=0.0432) but it did not have a significantly higher yield compared to cotton
(MoBio Ultraclean) or cotton (Qiagen) (Mann-Whitney U-test: W=22, p=0.146 and
W=17, p=0.6 respectively). It appears that the Catch-All swab using a Qiagen kit
gives the greatest DNA yield for oropharyngeal swabs. Samples from the oropharynx
gave a higher DNA yield compared to skin swabs.
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Figure 4.4: Comparison of DNA extraction kits and swab types on DNA yields for
oropharyngeal swabs.
Comparison includes dry swabs of Catch-All (MoBio Ultraclean) (n=5,µ=0.119ng/µL,
σ=0.273) Catch-All (Qiagen) (n=9, µ=1.03ng/µL, σ=1.48), Cotton (MoBio Ul-
traclean) (n=3, µ=0.132ng/µL, σ=0.093), Cotton (Qiagen) (n=3, µ=0.263ng/µL,
σ=0.059).
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The protocols from Qiagen for the QiaAMP minikit include a Buccal swab protocol,
in addition to the Tissue protocol. Previously, we have used the Tissue protocol with
success for processing oropharyngeal swabs. The major difference in the buccal swab
protocol surrounds using greater quantities of buffer AL to ensure sufficient cell lysis
in the larger sample volume. There were no significant differences on DNA yields be-
tween buffer volumes for ACF (Mann-Whitney U-test: W=11, p=0.195), axilla (Mann-
Whitney U-test: W=8, p=0.082), nare (Mann-Whitney U-test: W=9, p=0.275), and
oropharynx (Mann-Whitney U-test: W=23, p=0.536). Greater volumes of buffer AL
lead to greater DNA yields using the Qiagen kit (see figure 4.5).
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Figure 4.5: Effect of increased buffer volumes in Qiagen kits on DNA yield.
Comparison is of swabs all processed using the Qiagen kit. Swabs were from ACF with
200µL AL (n=8, µ=0.017ng/µL, σ=0.027), ACF with 400µL AL (n=3, µ=0.035ng/µL,
σ=0.020), axilla with 200µL AL (n=9, µ=0.038ng/µL, σ=0.050), axilla with 400µL AL
(n=3, µ=0.252ng/µL, σ=0.319), nare with 200µL AL (n=10, µ=2.257ng/µL, σ=4.112),
nare with 400µL AL (n=3, µ=2.490ng/µL, σ=0.320), oropharynx with 200µL AL
(n=9, µ=0.842ng/µL, σ=1.311), and oropharynx with 400µL AL (n=3, µ=0.265ng/µL,
σ=0.125).
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Figure 4.6: Effect of 4µL ReadyLyse lysosyme (MoBio) on DNA yields.
Comparison includes ACF swabs with lysosyme (n=3, µ=0.523ng/µL, σ=0.438) and
ACF swabs without lysosyme (n=5, µ=0.013ng/µL, σ=0.030). All swabs moistened
with PBS.
DNA yields from ACF swabs with 18 hour incubation with 4µL of ReadyLyse
lysosyme (MoBio) prior to extraction following manufacturer’s instructions ensures
much greater DNA yield than without lysosyme in ACF swabs using the Qiagen kit
(see figure 4.6). There were no significant differences in DNA yields between ACF
swabs treated with lysosyme and those not treated with lysosyme (Mann-Whitney
U-test: W=14, p=0.057).
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Figure 4.7: Effect of three cycles of freeze thawing on DNA yields from swabs. Snap
freezing performed in ethanol-dry ice slurry followed by thawing in a 37◦C heating
block for 10 minutes.
Comparison includes ACF swabs freeze thawed (n=3, µ=0.011ng/µL, σ=0.011) and
not freeze thawed (n=3, µ=0.009ng/µL, σ=0.015), and oropharynx swabs freeze thawed
(n=3, µ=0.119ng/µL, σ=0.020) and not freeze thawed (n=5, µ=0.109ng/µL, σ=0.251).
All swabs moistened with PBS.
Figure 4.7 demonstrates that freeze thawing decreases the yield from MoBio Ultr-
aclean kits for both ACF swabs (representing a low DNA yielding sample type) and
oropharyngeal swabs (representing a high DNA yielding sample type). There were
no significant differences in DNA yield between samples freeze-thawed and those not
freeze-thawed in both ACF and oropharynx swabs (Mann-Whitney U-test: W=5, p=1
and W=18, p=0.106 respectively).
Figure 4.8 demonstrates the DNA yields possible from swabs of the entire forearm
with different MoBio kits using the Catch-All swab moistened in different reagents.
There were no significant differences between yields in forearm DNA extraction methods
(Student t-test: t=-2.48, p=0.134 when distributions with greatest difference in means
were compared). However, the DNA yield possible with entire forearm swabs moistened
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Figure 4.8: Comparison of different DNA extraction methods for forearm swabs
Comparison includes forearm Catch-All swabs moistened with SDW processed with
MoBio Bacteremia kit (n=3, µ=0.015ng/µL, σ=0.002), MoBio Powersoil kit (n=3,
µ=0ng/µL, σ=0), and MoBio Ultraclean kit (n=3, µ=0.045ng/µL, σ=0.005).
with SDW and processed in the MoBio Ultraclean kit is higher than that achieved with
ACF swabs, as seen in figure 4.1.
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Figure 4.9: Comparison of different methods of concentrating DNA (percent loss of
ng/µL.
Comparison includes samples concentrated with Ampure XP beads (n=5, µ=47.6%,
σ=32.8), ethanol precipitation (n=5, µ=48.9%, σ=21.5), and vacuum using SpeedVac
(n=5, µ=53.0%, σ=18.5).
Due to the small quantities of DNA recovered from skin swabs, a greater elute was
employed of 100µL to gain more DNA, although in a larger volume. Concentrating
samples was necessary to provide sufficient DNA quantities for library preparation (1-
5ng in 10.5µL). DNA was concentrated using each of the methods detailed in figure 4.9.
There were no significant differences in percent DNA concentration loss between differ-
ent methods (Student t-test: t=0.318, p=0.761). It is evident that concentrating DNA
using the SpeedVac leads to the least loss in DNA quantity, in addition to being the
least costly and technically challenging.
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4.3 Discussion
Measures of DNA quality resulting from DNA extractions were not systematically
recorded as the library preparation process involves cleaning of DNA, removing com-
pounds which are problematic in downstream sequencing and the quantities of DNA
obtained would not result in a visible result on an ethidium bromide gel until pooled
in a higher concentration. For quantification, qPCR may have been more successful
in detecting low copy number of 16S and could discriminate between bacterial and eu-
karyotic DNA using universal primers for 16S, as used in the library preparation efforts
in this study (F515Knight/806Reverse). The disadvantage of this approach would be a
larger volume of sample employed in performing qPCR in triplicate. Qubit quantifica-
tion through fluorometry still remains highly replicable[177], and is as such suitable for
a study investigating differences between DNA extraction approaches where eukaryotic
DNA burden is likely to be minimal due to use of swabs.
In addition, sampling from the entire forearm and hand means that a wide range of
niches are sampled meaning that it could be argued that community ecology measures
are not representative of a single population (for example, the ACF and hand provide
distinct niches for different bacterial communities)[160]. Though this is a weakness,
and individual samples of each niche would have been more fitting, it must be balanced
against cost and the time subjects spend being sampled. Furthermore, although the
samples taken are not representative of specific communities, the pooled communities
sampled are comparable to one another in this study. Improvements to this study could
have included taking multiple swabs from the same subject on the same occasion and
pooling multiple DNA extracts, which would have likely increased the final quantity of
DNA yielded. Other approaches could include performing a greater number of cycles
within the PCR steps of library preparation, however this may introduce greater error
which already comprise the greatest proportion of errors observed in 16S sequencing[75].
An approach which may reduce these errors while still enabling greater amplification
of the library has been taken by Grice et al.[178] whereby replicate samples are taken
for PCR in library preparation and in one sample, Sybr Green is used (providing a
fluorescent signal) to determine on an individual sample basis how many cycles can be
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obtained on the parallel samples with Taq polymerase (suitable to provide products
for downstream sequencing) without exceeding the linear range of the reaction. The
downsides of this are the greater quantities of DNA required to monitor progression of
the PCR and the intensive nature of monitoring individual reactions. Solutions further
downstream may include pooling larger numbers of samples with lower quantities of
DNA, however it is difficult to ascertain the necessary read-depth to draw accurate
conclusions from a microbiome study[77].
The method of sampling is important in terms of DNA yield. In this study, it
was noted that Catch-All swabs performed best for DNA yield in all sites apart from
nare where cotton swabs performed better. Catch-All swabs are soft foam brushes
that appear to be generally more reliable in transferring bacterial populations from
site to tube. Cotton swabs may have performed better in the nare due to greater
possibility of removing organic debris since these brushes are thicker. Initially, the
human microbiome project used blunt scalpels to scrape skin, however this was later
changed to MoBio Catch-All swabs due to high levels of eukaryotic DNA which lead to
problems performing metagenenomic sequencing[160]. Since this study performs PCR
for bacterial 16S regions, leading to bacterial DNA amplicons, high levels of eukaryotic
DNA in the sample would not problematic. The benefits of gaining higher DNA yields
using this method, however, must be weighed against the potential distress caused to
a child who is sampled in this manner. As such, it was decided to perform the final
cohort of sampling using a MoBio Catch-All swab.
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Chapter 5
16S amplicon sequencing
5.1 Introduction
Since the advent of next-generation sequencing, microbiome studies have become in-
creasingly more affordable to conduct.
Illumina have a range of sequencing platforms; MiSeq and HiSeq are currently the
most commonly used and differ primarily in their readlength and output[179]. MiSeq
generates up to 300bp dual index reads, whereas the HiSeq generates up to 150bp reads.
The HiSeq is designed for large-scale genome projects, outputting over 50Gb of data
per day, compared to the Miseq which is designed for smaller scale sequencing, and
can output 1.5Gb per day. As such, Illumina MiSeq is generally better suited to 16S
amplicon sequencing due to the longer read length possible.
Illumina flow cells have oligonucleotides bound to the membrane which bind to
Illumina adaptors, at both the 3’ or 5’ end[180]. This allows for sequencing of both DNA
strands and identification of them using barcodes. There are two methods employed to
enable dual index sequencing[181]. The first involves two rounds of PCR; in the first,
the primers anneal to the region of interest with an overhang to link to the Illumina
index and adaptor, while in the second primers anneal to linker and have an overhang
of the Illumina index and adaptor. This has the limitations of requiring multiple PCR
cycles, thus increasing the rate of PCR error. A second approach involves only one PCR
cycle of forward and reverse primers with the Illumina pad-linker-primer combination
already. The purpose of the pad in this case is to prevent hairpin formation. This
has the advantage of limiting PCR cycles. The dual index approach can also produce
longer reads by not completely overlapping the regions subject to PCR, thus extending
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readlength up to 500bp.
Both platforms employ sequencing by synthesis, whereby reversible terminator dye
nucleotides are incorporated into a genomic DNA clusters anchored to the flow cell
(a chamber within the machine)[96]. First, genomic DNA (under 600bp long) with
Illumina adaptors[96, 181] attached to each end of the DNA strand is placed in the flow
cell where the DNA fragments anchor to the surface of the flow cell via the adaptors[96].
The DNA fragments then undergo isothermal PCR, forming individual clusters[96].
During each sequencing cycle, engineered DNA polymerase adds a fluorescently labelled
nucleotide to anchored DNA fragments, after which a laser excites the fluorophore and
a camera captures the image, after which the fluorophore is cleaved and the process
start again[96]. Each sequencing run may involve hundreds of cycles.
Sequencing errors specific to Illumina chemistry include long homopolymer tracts
and also GGC motifs in GC-rich zones[182]. Illumina requires heterogenous base com-
position within the libraries[182], as such it is often necessary to introduce higher genetic
diversity through spiking the library with greater quantities of the control, PhiX[181].
The overall error rate of Illumina is under 0.4%[182].
Pyrosequencing was pioneered by Roche, culminating in the 454 GS-FLX (454
Life Sciences) and was arguably the first high-throughput sequencing technology avail-
able[95]. Initially a picotitre plate, each of the 1.7 millions wells with a bead that
only binds one DNA fragment is introduced, followed by PCR creating many identical
fragments on the same bead, and melting rendering the sample ready for sequenc-
ing. Pyrosequencing[95] is a sequencing by synthesis technology, whereby natural nu-
cleotides are incorporated to a DNA strand with DNA polymerase, each time releasing
a pyrophosphate group. An enzymatic cascade follows of pyrophosphate converting to
ATP via sulphurylase followed by ATP use by luciferase to emit light which is then
detected by a high resolution camera (using fibreoptic bundles attached to a charge
coupled device). This sequencing technology gains on average, 400bp reads[95].
Pacific Biosciences released a sequencing platform, the PacBio RSII[183], which per-
forms single molecule real-time (SMRT) sequencing through direct observation of DNA
polymerisation incorporating fluorescently labelled nucleotides. Zero-mode waveguide
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is employed, allowing direct observation of fluorescence at volumes orders of magni-
tude lower than confocal fluorescence microscopy[184]. It bypasses the need for PCR,
although requires higher quantities of input DNA[182]. Unlike other technologies, the
fluorophore is attached to the phosphate backbone of dNTPs, allowing uninterupted
synthesis, and thus rendering it suitable for real-time observation[183]. This technol-
ogy achieves readlengths several kilobases long, with some reads over 10,000kb[185]. In
addition, this technology is able to observe methylation patterns which is desirable in
an era where bacterial epigenomics is of growing interest[186]. The error rate is high, at
13% and distributed evenly through the reads[182], however this can be reduced to neg-
ligible quantities by performing more sequencing cycles to find consensus bases (known
as circular consensus sequencing technology) or mapping with high quality short reads
obtained from the same genome[187]. The aims of this chapter are to gain sequencing
results from the V4 region of the 16S gene from DNA extracted from the second cohort
of samples where forearm, axilla, nare, and oropharynx were sampled. In addition, a
swab negative (DNA extracted from a swab with no sampling) and a PCR negative
(DEPC water put through the library preparation) will be included in the sequencing
run to assess contamination.
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5.2 Results
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Figure 5.1: Loss in DNA quantity during library preparation for each sample type
Figure 5.1 demonstrates the quantity of DNA lost following library preparation.
The DNA concentration of the DNA extraction product demonstrates the yields ob-
tained using MoBio Ultraclean protocol finalised by optimisation. The pooling strategy
for different sample types was derived from DNA concentration of the library for each
sample type. Given the great differences between DNA quantity available from each
sample type, a pooling strategy was applied whereby each sample type is input at ap-
proximately similar concentrations for sequencing. A full table of DNA concentrations
obtained from extraction after concentration with SpeedVac, library DNA concentra-
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tions obtained, and pooling strategy is given in the appendix.
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Figure 5.2: Quality check electrophoresis gel
This gel (lane 4) demonstrates bands of intensity, corresponding to concentration of
DNA according to length of fragments (bp) in the library. The ladder (lane L) provides
a reference.
Figure 5.2 demonstrates the electrophoresis gel on the entire pooled DNA sample
from the Bioanalyzer as part of quality checks prior to sequencing. The majority of
DNA was approximately 450bp length, matching the expected size of the V4 hyper-
variable region. There is a small band of approximately 150bp length which likely
represents small fragments of primer-dimer introduced during the library preparation
PCR cycles.
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Peak table for sample 4  :  5122
Peak Size [bp] Conc. [pg/µl] Molarity [pmol/l] Observations
1 35 125.00 5,411.3 Lower Marker
2 69 20.30 444.4
3 75 12.93 260.3
4 127 10.44 124.8
5 170 84.26 749.0
6 187 7.89 64.1
7 198 17.01 129.8
8 441 97.67 335.9
9 453 311.10 1,041.1
10 699 10.14 22.0
11 2,966 1.60 0.8
12 10,380 75.00 10.9 Upper Marker
13 12,724 0.00 0.0
Region table for sample 4  :  5122
From
[bp]
To [bp] Corr.
Area
% of
Total
Average Size
[bp]
Size distribution in
CV [%]
Conc.
[pg/µl]
Molarity
[pmol/l]
Co
lor
401 513 547.6 64 452 2.7 413.80 1,388.0
5122
Overall Results for sample 4  :  5122
Number of peaks found: 11 
Noise: 0.2 
Corr. Area 1: 547.6 
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Figure 5.3: Quality check electropherogram
This quality check electropherogram demonstrates quantities of DNA according to size
(bp) of fragments in the library.
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Figure 5.3 shows the electropherogram from Bioanalyzer quality check prior to
sequencing. This graph demonstrates the same result as seen in figure 5.2, that there is
an expected peak of 453bp and a smaller peak of 441bp consistent with V4 hypervariable
region and many smaller peaks of small fragments likely to be primer-dimer as a result
of library preparation PCR.
Due to the primer-dimer, further clean-up of the sample was undertaken using Am-
pure beads (performed by the Centre for Genomic Research, University of Liverpool).
The pooled sample then passed quality checks and proceeded to sequencing on the
Illumina MiSeq (performed by Centre for Genomic Research, University of Liverpool).
Following sequencing, some barcodes could not be detected due to low input quan-
tities of DNA. The assembled reads are shown in table 5.4. It demonstrates the uneven
results between samples from sequencing. Following quality control of those assembled
reads, 42 of the original 70 samples including negative controls remained for analysis.
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Figure 5.4: Reads resulting from samples.
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Figure 5.5: Alpha diversity of samples estimated on rare OTUs present.
Alpha diversity of samples, chao1, is shown in figure 5.5. High diversity appears to
correspond with those samples with high biomass and read count as seen in figure 5.4.
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Figure 5.6 shows those taxa which could be identified to species or genus level that
comprise > 1% of any sample across all subjects and including the negative control
swab. It is clear there is a great deal of overlap in taxa identified in CF subjects,
healthy controls and the patient with equivocal diagnosis. Acinetobacter was found
only in nare of subject 16, a CF patient who had not isolated this in clinic swabs from
in the previous year. H. influenzae was found in nare of subject 14, a CF patient
who had previously grown this pathogen from clinic swabs. H. influenzae was also
found in the oropharynx of subject 16, a CF patient who had not had this pathogen
isolated in the previous year and in this study was the only taxon found in this sample
alongside other Haemophilus and Veillonella dispar. H. influenzae was also found in
the nare of subject 35, a healthy control. Only two samples were found to contain
Pseudomonas, the oropharynx of subject 18, a CF patient, and nare of subject 28,
a healthy control. Strikingly, Prevotella, Rothia, Streptococcus and Veillonella species
were found abundantly across CF subjects and healthy controls in all sites. The negative
sample showed heavy Rhodococcus reads, which was not found in any other sample.
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Figure 5.6: Heatmap of all samples showing relative abundance of all taxa reaching
genus/species level which comprise > 1% in any sample.
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Figure 5.7: Heatmap of skin samples showing relative abundance of all taxa reaching
genus/species level which comprise > 1% in any sample.
Figure 5.7 is a heatmap of all skin samples from CF patients and healthy controls
showing taxa which comprise > 1% of any sample. It highlights the similarities between
taxa found on forearm and axilla in both CF patients and healthy controls. Subject
32, a healthy control was found to have Haemophilus as the dominant taxon on the
forearm in contrast to the other subjects where it is largely absent. The low abundance
of Staphylococcus is also notable being found only in the axilla of two subjects.
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Figure 5.8 shows a heatmap of taxa representing > 1% of any sample in nare
and oropharynx of CF patients and healthy controls, of which there appears to be
significant overlap. Predominant differences include Staphylococcus, Alloicoccus, Cor-
neyebacterium, and Moraxella which appear to be largely present in CF and healthy
subjects in the nare but not oropharynx. In addition, Haemophilus species seem to be
found more frequently in the oropharynx compared to the nare of both CF and healthy
subjects.
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Figure 5.8: Heatmap of nare and oropharyngeal samples showing relative abundance
of all taxa reaching genus/species level which comprise > 1% in any sample.
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Figure 5.9: Venn diagram showing overlap in each site from CF patients of taxa iden-
tified to genus/species level comprising > 1% of any sample.
A Venn diagram demonstrating overlap of taxa at genus/species level in CF pa-
tients which represent > 1% of any sample is shown in figure 5.9. There is significant
overlap at all sites of eight taxa including Streptococcus, Rothia mucilaginosa, Neisse-
ria, Prevotella melaninogenica, and Veillonella dispar. Of interest, other Prevotella and
Veillonella species are found in both nare and oropharynx though this is not found with
Pseudomonas or Haemophilus species which can be found primarily in the oropharynx.
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Figure 5.10: Venn diagram showing overlap in each site from healthy controls of taxa
identified to genus/species level comprising > 1% of any sample.
Figure 5.10 shows overlap of taxa at genus/species level in healthy subjects which
represent > 1% of any sample. In the healthy subset, Veillonella can be found in all
sites, in addition to Rothia, Neisseria and Streptococcusas seen in the CF patients.
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Figure 5.11: Heatmap showing relative abundance of phyla across samples.
The distribution of phyla for all subjects is seen in figure 5.11. Firmicutes appear
to be in higher abundance in CF samples compared to healthy controls while Pro-
teobacteria appear higher in abundance in healthy controls compared to CF patients.
Actinobacteria appear to dominate the sample in the axilla and oropharynx of healthy
subjects 28 and 30 respectively. The negative control is dominated by Actinobacteria
due to the high read-count of Rhodococcus in the sample.
Heatmaps showing order, class and family taxa for all samples can be found in
Appendix E.
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5.3 Discussion
Illumina technology generates high-quality reads with a low error rate[182], and errors
specific to the technology, such as difficulty with homopolymer tracts should not be of
importance in amplicon sequencing. Compared to the Illumina HiSeq, the MiSeq pro-
duces longer read lengths (300bp compared to 150bp) but produces a lower data output.
This renders it an obvious choice for small microbiome projects where a readlength
capable of sequencing an entire hypervariable region is necessary. On average, 454-
pyrosequencing generates 400bp reads, and this is still among the longest for next gen-
eration technologies today. It carries an average error rate of 1.07%, which are more
common in homopolymer tracts, with longer reads there were an increased frequency
of mismatch errors and ambiguous bases tending to occur at the end of the read, and a
higher frequency of indels are found in particular spacial distributions of the sequenc-
ing plate[188]. This technology has largely been superseded by Illumina due to shorter
but higher quality reads. Despite this, many early microbiome studies employed this
technology. PacBio is able to characterise the full complexity of genomes, including
repeating motifs, and as such is ideal for large scale genomics or to provide high quality
reference genomes[183]. Despite criticism of its application in microbiome studies[189],
likely due to the high error rates observed superficially, it has been used for this appli-
cation with success[190]. With greater read lengths, a greater phylogenetic resolution
can be obtained, assuming the error rate is reduced as discussed previously[190]. Cost
and required input quantity of DNA is likely to make this technology prohibitory for
most microbiome studies. Given the comparison of sequencing options, Illumina Miseq
was clearly the appropriate choice for this study.
The 16S region comprises nine hypervariable regions, of which we chose hypervari-
able region 4 (V4) for amplicon sequencing. Each hypervariable region has a different
pattern of sensitivity for particular genera. We chose V4 due to the length (approxi-
mately 450bp) rendering it suitable for sequencing on Illumina Miseq, and the lack of
intragenomic heterogeneity found within it[88]. Increased intragenomic heterogeneity
leads to an artificial increase in diversity within a sample, introducing greater error into
comparative studies. Most skin microbiome studies have employed V1-V3 due to its
95
sensitivity to detect dominant skin commensals, such as firmicutes[191]. In designing
a microbiome study, it is important to balance the practicality of downstream analysis
resulting from choice of hypervariable region sequence and the sensitivity to detect the
expected genera. Some studies have employed several hypervariable regions for this
region, however cost and difficulty in analysing data resulting from this approach is a
limiting factor.
Due to the low quantities of DNA yielded from skin swabs, and the necessary un-
even pooling, there are limitations on the manner in which data from this study can
be analysed. Uneven pooling of the DNA samples naturally leads to a greater read
depth in particular samples over others due to the higher number of copies present in
the sequencing flow cell. As such, a greater degree of variation may be observed in
those with a greater read depth; α-diversity is a function of read depth[192]. Sample
types with similar input DNA quantities can be compared to one another in terms of
community ecology measures, however these measures cannot be compared between
different sites. This prevents analysis of relationships between diversity of oropharyn-
geal microbiota and skin microbiota, which could have revealed whether the decline in
diversity observed in the airways over time is linked to a systemic decrease in microbial
diversity. It was important to include negative controls of both the swab itself and the
PCR step in the library preparation due to the low biomass sample present; that in low
DNA quantities, there may be a greater proportion of background noise from contam-
ination. Encouragingly the PCR negative did not have enough reads to meet quality
cut-off to be analysed and the swab negative showed predominantly Rhodococcus, a
bacterial genus which inhibits soil and is frequently isolated from DNA extraction and
PCR kits[176] probably related to their manufacture in low-oxygen environments which
allow nitrogen-fixing bacteria to thrive.
This study found significant overlap of taxa between all sites in both CF patients
and healthy controls. Notably, Veillonella and Prevotella, Gram-negative anaerobes
recently postulated to have a role in CF infection[136, 193], were found in both nare and
oropharynx of CF patients. This reinforces the theory that the upper respiratory tract
may be a niche which offers pathogens relative protection from the immune response and
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antimicrobial therapy compared to the lower respiratory tract, thus creating a reservoir
of pathogens which can eventually seed back to the lower respiratory tract[112, 115].
Alpha diversity measures appeared to be highest in samples with a high read count
limiting the conclusions that can be drawn from this measure. In further studies if even
pooling could be achieved this would be a useful measure to determine early changes
in population structure of skin and upper respiratory tract that may be implicated
in disease progression in CF, as has previously been demonstrated in sputum samples
from adults with CF[125].
At phylum level, it appears that CF patients tend to have a higher abundance of
Firmicutes compared to healthy controls, while healthy controls have a higher abun-
dance of Proteobacteria across all sample types. This appears to be contradictory to
the assertion the CF lung microbiome has a dominant fraction of proteobacteria com-
pared to healthy lung microbiome[123]. Previous studies only investigated adults with
CF for phylum-level differences who may have more advanced lung disease and thus
a more distinct microbial signature. In addition, this study only investigates samples
from the upper respiratory tract and skin which may not be representative of samples
from the lower respiratory tract. The high abundance of Firmicutes is reflected in
the frequent identification of Veillonella and Streptococcus and infrequent identifica-
tion of Pseudomonas. There are also some unculturable phyla present at low levels,
Gracilibacteria(GN02) and Saccharibacteria (TM7) which did not resolve below order
level so their significance cannot be determined. Thermi were also found which is likely
Thermus aquaticus DNA contamination from PCR reagents.
Strikingly, Prevotella and Veillonella, anaerobic Gram-negative bacteria were found
on the skin of CF patients and healthy controls in addition to the upper respiratory
tract. The skin is an unexpected environment for even a low abundance of anaerobic
bacteria. Since 16S microbiome studies may identify DNA from dead as well live
bacteria, these reads could represent dead bacteria which have been transferred from
other niches where these may be commensals. It is unlikely this is sample contamination
as the swab negative control did not contain either of these genera. Other possibilities to
consider are that all subjects had contact with the hospital environment and may have
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acquired these genera from contact with other patients and the hospital environment.
Finding Prevotella and Veillonella on the skin of CF patients and healthy subjects is
an important finding that deserves further study to confirm the possibility of carriage
on skin and in the upper airways given the role these anaerobes likely have as CF
pathogens[136, 193].
Streptococcus was also found abundantly on all sites in CF patients and healthy
controls, however this is a normal skin commensal[160] was also found in the negative
control, limiting the significance of this finding. Staphylococcus was interestingly absent
from most samples which would be expected to form a significant proportion of the skin
microbiome[160]. This finding is also in conflict with the culture results obtained from
the same patients. This is probably due to difficulty of extraction given these are
Gram-positive bacteria, reinforcing difficulty of extracting DNA for studies of the skin
microbiome[160]. This is study used beadbeating and lysozyme treatment to increase
yield of DNA. Use of harsher protocols to increase yield carry the risk of shearing DNA
decreasing its quality for sequencing[176] and use of more abrasive sampling techniques
may have reduced recruitment given increased discomfort. This indicates that the skin
microbiome presented in this study does not represent the full diversity of the skin
microbiota present in these subjects.
98
Chapter 6
General Discussion
This study has demonstrated a culture-based core microbiota of Staphylococcus and Mi-
crococcus universal to both CF patients and healthy controls across all sites. Pathogens
have been found on the skin of both CF patients and healthy controls, however this is
infrequent and not present in sequential samples, suggesting it is a transient microbiota,
in agreement with the limited literature suggesting this[161]. In addition, issues of low
biomass samples from the skin became apparent with extremely low DNA yields from
swabs, which has been a feature recognised elsewhere[162]. This study has contributed
to an optimised protocol, however has not succeeded in providing high enough yields
that skin microbiota may be compared to the DNA yields of other sites to fulfill even
pooling of a maximum sequencing capacity. The samples obtained from 18 CF patients
recruited, 17 healthy subjects, and one subject with equivocal diagnosis has undergone
amplicon sequencing of the V4 hypervariable region of 16S, and will likely generate
interesting results of a preliminary study into the landscape of CF skin, however unfor-
tunately it was not possible to present the data in this thesis. Subjects with equivocal
diagnosis of CF have never been subject to a comprehensive microbiological investiga-
tion. Although only one subject was recruited in this feasibility study, it may provide
important insights to their airway microbiome in this emerging diagnosis where there
is a great deal of debate over best practices in monitoring colonisation in clinics[31].
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Pathogens had been isolated at a variety of sites in each patients, and not always
on the hands as might be expected. However, a similar pattern was seen in healthy
subjects. This may imply a common route by which CF pathogens, such as P. aerugi-
nosa, gain entry to the respiratory tract in children, leaving those who have CF prone
to colonisation of the respiratory tract. This is in agreement with literature suggesting
that transmission of pathogens occur with direct contact[153, 154, 170]. However, these
studies only examined the hands of CF patients and recruited no healthy controls. In
examining several sites, we demonstrate that P. aeruginosa may be present in any of
these regions without being present on the hand. Although it is clear that over a period
of months the colonisation is transient, the length of colonisation normally cannot be
ascertained and these niches may play a role in harbouring pathogens prior to infec-
tion. The significance of an isolated finding of Pseudomonas in the axilla is unclear from
this work but raises the possiblity that hand hygeine may not be adequate to prevent
transmission of pathogens and raises the possiblity of wider hygeine interventions to
control infection in CF. The possibility that community structure may render CF skin
more prone to transient pathogens may become clearer after analysis of the microbiome
data. Considering the high salt content of CF skin, it may be hypothesised that this
provides a specific niche free of many genera contributing to healthy microbiota, and
thus could provide a niche where an invasive species is more likely to thrive. Further
work on this perspective would comprise long-term studies with sequential sampling of
skin microbiota and strain typing of pathogens.
It is also not clear whether there are differences in characteristics of pathogens iso-
lated from skin compared to those from the oropharynx in CF patients and healthy
controls. This will form part of further work emanating from this study, particularly
in characterising the strain type and phenotypic characteristics such as auxotrophy
and virulence of Pseudomonas and S. aureus isolated in this study. Further under-
standing of the characteristics of pathogens in transient skin microbiota may lead to
an understanding of how infection is established in CF.
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The vast majority of microbiome studies in CF have concentrated on the airways,
the site of chronic infection[194]. These have drawn conclusions focused on the com-
munity ecology of the CF lung, generating hypotheses for community interactions,
and identification of novel pathogens which commonly evade culture-based techniques.
Many key questions in these areas can be addressed by examining microbiomes outside
of the lung.
Decreased α-diversity of the lung microbiome is thought to be have a central role
in CF exacerbation and is associated with decreased lung function over time[127, 131],
however the reasons behind this are unclear; decrease in diversity may relate to antibi-
otic therapy, high systemic levels of inflammatory cytokines, local inflammation in the
lung parenchyma, or colonisation with an invasive species. In studying microbiomes
outside of the CF lung, it would be possible to observe whether the decrease in microbial
diversity is systemic or local to the lung, narrowing the possible reasons for the change
in diversity observed. Furthermore, we observed it is possible to identify pathogens on
the skin of CF patients, so it may be possible if studying sequential samples over time,
to track the transmission of an invasive species into the lung microbiota and elucidate
determinants of infection. Studies of this kind will likely inform the design of robust in-
terventional studies in murine models or alternative systems for studying interventions
in microbiomes, such as the cheese rind model[195].
This study demonstrated significant overlap in genera in each niche in both CF pa-
tients and healthy controls. There is mounting evidence the the upper respiratory tract
is a niche where P. aeruginosa diversifies and evolves to then seed to the lower respi-
ratory tract[108, 109]. Finding potential pathogens such as Prevotella and Veillonella
in the nare and oropharynx may indicate they have adapted to niches in the upper
respiratory tract for a similar end. It would be worthwhile exploring this further with
whole-genome sequencing of these anaerobic bacterial populations in the nare, orophar-
ynx, and lower respiratory tract to explore the possibility of the upper respiratory tract
as a niche allowing for diversification and adaptation to the lower airways.
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This study also demonstrated only S. aureus in some patients with CF but not
healthy controls. It is known that carriage of S. aureus is higher in CF patients com-
pared to healthy controls and that it is a predominant pathogen in childhood CF but
that this can be reduced with antistaphylococcal antibiotics[49]. Another interpreta-
tion of this is that S. aureus carriage in all sites of this population was dramatically
lower than reported in other studies of children such as Goerke et al who report 29%.
This could indicate a weakness of this study in a lack of sensitivity for detecting S.
aureus since this study lacked funding to use tube coagulase test or MALDI-TOF. The
finding of S. aureus only in subjects with CF and no healthy controls should prompt
further investigation in larger studies with more appropriate identification methods for
S. aureus. Further studies should also evaluate the impact of S. aureus carriage on the
progression of CF lung disease and the potential role for topical S. aureus decolinisation
in this population.
Through lung microbiome studies, difficult to cultivate bacteria have emerged as
potential pathogens when found to be a dominant genera in the CF lung, such as the
Gram-negative anaerobic bacillus Prevotella[136]. Prevotella is a member of normal
microbiota in the oral cavity and gut, however it is not clear whether this is a CF
pathogen and how transmission from the environment occurs. It seems unlikely that
anaerobic bacteria are transmitted via the skin, however finding of these genera on the
skin in this population of CF patients and healthy controls should lead to further studies
to confirm this. Performing comparative microbiome studies on oral and gut microbiota
may further help elucidate the mechanism by which anaerobic bacteria inhabit the CF
lung, and how much the contents of the gut, oral cavity, and skin can influence the
composition of the CF lung.
In performing a feasibility study for the skin microbiome in cystic fibrosis, we have
successfully characterised the difficulties in DNA extraction from swabs, and have iso-
lated pathogens from different sites on the CF patient and healthy controls where
further characterisation will determine any changes in behaviour of these pathogens
specific to the niche they inhabit. Analysis of the microbiome data has revealed shared
taxa between the skin, nare, and oropharynx to form a starting ground whereby larger
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studies can examine the temporal relationships between the dynamics of this ecosystem.
In addition, the skin microbiome of cystic fibrosis will be defined over both the axilla
and forearm and hand. The strengths of this study are the rigorous attention to detail
in optimisation of DNA extraction from a range of sample types to find an acceptable
balance of yield between types, and in collecting culture isolates from each site for fur-
ther analysis in the context of the microbiome data. Weaknesses may include sampling
of entire forearm and hand which are arguably two very different niches, and as such
cannot produce informative or reproducible community ecology metrics. In addition,
the uneven pooling necessary to produce a library for sequencing forfeits potential as-
pects of analysis (particularly between different sample types within the same patient).
Given the small patient sample and difficulties generating microbiome data from low
biomass samples it was also impractical to stratify patients based on clinical data or
hygeine data. In further studies, it would be useful to stratify based on these measures
to explore any associations between clinical state or hygeine measures and pathogen
acquisition, as well as any difference in community structure of the microbiome on the
skin and in the respiratory tract.
A further limitation is the use of children attending surgical outpatient appoint-
ments as healthy controls. All these subjects had contact with the hospital environment
and some had a history of medical conditions and surgical procedures.
Potential pathogens have been isolated from surfaces in hospital environments, in-
cluding S. aureus, P. aeruginosa and multi-drug resistant organisms [196, 197]. Evidence
of biofilm formation despite cleaning with chlorine solutions was also found in one study
set in an intensive care unit [Hu2015]. To date, no studies have examined microbiota in
the outpatient environment. Inpatient settings may have more prolonged exposure to
patients with bacterial infections compared to outpatient settings so it could be specu-
lated outpatient settings are less likely to harbour pathogenic microbiota. Conversely,
the same healthcare professionals work in both inpatient and outpatient areas and may
carry pathogens between these settings on clothing [198]. The control subjects in this
study could have potentially acquired a hospital-associated microbiota from their sur-
roundings. Common exposure to the hospital environment for both healthy controls
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and children with CF could have resulted in observing similar microbiota, however
this may also have helped in identifying a CF-specific microbiome independent of the
hospital-associated microbiota.
Control subjects may have previously been exposure to the inpatient environment
for surgical procedures and may have had exposure to broad-spectrum antibiotic ther-
apy as prophylaxis to surgical wound infections. Jernberg et al. [199] studied a group
of healthy adults exposed to 7 days of clindamycin, detecting changes in faecal micro-
biota, specifically decrease in Bacteroides diversity, lasting throughout follow-up of two
years. Although the authors did not examine other microbial niches and did not in-
clude children, it suggests that broad-spectrum antibiotics can cause long-term changes
in host microbiome and this may have impacted the observed microbiome in control
subjects in this study. Previous use of broad-spectrum antibiotics may have long-term
impacts on the control subject microbiome, possibly rendering it unrepresentative of
the healthy microbiome.
Although there are limitations of the control group employed by this study, this
group of healthy children remain the most appropriate to use within the scope of the
protocol approved by the research ethics committee. Recruiting healthy children from
the community would not have been practicable given the further ethical approvals
needed and anticipated difficulties in recruitment.
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Future work on this study should include full characterisation of bacterial and
fungal isolates. Identification to species level should use an appropriate technology,
such as MALDI-TOF as previously discussed, investigation of phenotypic characteris-
tics, such as motility, auxotrophy, quorum sensing markers, and virulence. Initially,
high-throughput methods using Galleria could be employed to assay virulence prior
to selecting representative strains for testing in murine models. In addition, further
characterisation of selected isolates could be undertaken using whole-genome and tran-
scriptome sequencing to find candidate genes necessary for survival of pathogens on the
skin. Coupled with probing more specific skin sites in CF subjects and healthy con-
trols, this would provide a step forward in understanding the determinants of pathogen
survival in this environment and could identify potential therapeutic targets. Further-
more, clinical trials may be undertaken to examine the effects of more rigorous hygeine
routines on frequency of pathogen colonisation.
This has successfully provided a bacterial and fungal collection of isolates for further
work with linked clinical data. In addition, it has provided 16S amplicon sequences of
samples from skin and upper respiratory tract of CF patients and healthy controls,
though unfortunately DNA yield from skin samples was inadequate despite extensive
optimisation using a variety of extraction methods and swab types. Further studies
should examine use of more abrasive sampling methods while considering issues of
recruiting in the paediatric population where subject discomfort is a major problem
to recruitment into observational studies. In addition, more robust DNA extraction
protocols to target Firmicutes are necessary given the low numbers of Staphylococcus
identified in the microbiome study is likely due to problems with extraction, especially
in view of their frequent isolation in the culture study. This study has provided a
starting point for a great deal of work on the subject of comparative microbiomes in
cystic fibrosis which may help answer some of the pivotal questions surrounding the
CF microbiome.
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Appendix C
Media and buffers
Blood-Columbia was prepared from Columbia media (Oxoid) with the addition of 5%
defibrinated horse blood (Fisher Scientific) following autoclaving and cooling of media
to 60◦C.
Carbohydrate fermentation broth (ASM microbe library) was prepared by adding
10g Proteose Peptone (Difco), 5g NaCl (Sigma), and 0.018g of phenol red (Sigma)
to 800mL volume. pH was adjusted to 7.4 using Tris (Sigma). This base media is
autoclaved, and then after cooling, a preparation of 10g carbohydrate (all produced
by Sigma) dissolved in 200mL SDW is syringe filtered (Appleton Woods, 0.2µL pore
diameter) into the broth.
Gelatin solid media (ASM microbe library) was prepared with 23g/L bacteriological
agar (Sigma) and 8g/L gelatin. This media was then autoclaved.
Christensen’s Urea solid media (ASM microbe library) was prepared with 1g/L pep-
tone (Oxoid), 1g/L Dextrose (Sigma), 5g/L NaCl (Sigma), 2g/L monobasic potassium
phosphate (Sigma), 20g/L urea (Sigma), 0.012g phenol red (Sigma). This media was
then autoclaved.
Luria-Bertani (LB) Lennox broth was prepared with 10g Bacto-Tryptone (Difco),
5g Yeast Extract (Oxoid), and 10g NaCl (Sigma) in 1L volume.
LB glycerol was prepared as above with the Lennox version of LB, with the addition
of 20% v/w of glycerol.
All other medias employed were produced from Oxoid, and manufacturer’s instruc-
tions were followed regarding their preparation.
Phosphate-buffered saline (PBS) was prepared according to instructions from Sigma.
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Tris-EDTA buffer was prepared using 10mM Tris in 1mM EDTA, adjusted to pH
8.0 with concentrated HCl
TE-Tween buffer was prepared by adding 1% Tween 20 to a preparation of Tris-
EDTA.
All buffers were autoclaved prior to use.
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Appendix D
Full culture and biochemical test
results
Subject identifier is given as ”ID”. Cystic fibrosis status is given as ”Y” for subjects
with CF and ”N” for subjects without CF. Aerophilic growth of the isolate is given as
”Y” if initially cultured in aerobic conditions, ”MA” is given if the isolate was originally
isolated in microaerophilic conditions. Carbohydrate names indicate whether the isolate
fermented to produce acid in the carbohydrate media provided. Pibwin score gives the
probability associated with the assigned identification.
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heatmaps
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Figure E.1: Heatmap showing relative abundance of bacterial orders across samples.
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Figure E.2: Heatmap showing relative abundance of bacterial classes across samples.
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Figure E.3: Heatmap showing relative abundance of bacterial families across samples.
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